



Published in final edited form as:

*Nat Rev Cancer*. ; 11(11): 775–791. doi:10.1038/nrc3151.

## Targeting protein prenylation for cancer therapy

Norbert Berndt<sup>\*</sup>, Andrew D. Hamilton<sup>‡</sup>, and Saïd M. Sebti<sup>\*.§</sup>

Saïd M. Sebti: [said.sebti@moffitt.org](mailto:said.sebti@moffitt.org)

<sup>\*</sup>Drug Discovery Department, Moffitt Cancer Center, 12902 Magnolia Drive, Tampa, Florida 33612, USA

<sup>‡</sup>University of Oxford, Vice-Chancellor's Office, Wellington Square, Oxford OX1 2JD, UK

<sup>§</sup>Departments of Oncologic Sciences and Molecular Medicine, University of South Florida, 12901 Bruce B. Downs Boulevard, Tampa, Florida 33612, USA

### Abstract

Protein farnesylation and geranylgeranylation, together referred to as prenylation, are lipid post-translational modifications that are required for the transforming activity of many oncogenic proteins, including some RAS family members. This observation prompted the development of inhibitors of farnesyltransferase (FT) and geranylgeranyltransferase 1 (GGT1) as potential anticancer drugs. In this Review, we discuss the mechanisms by which FT and GGT1 inhibitors (FTIs and GGTTIs, respectively) affect signal transduction pathways, cell cycle progression, proliferation and cell survival. In contrast to their preclinical efficacy, only a small subset of patients responds to FTIs. Identifying tumours that depend on farnesylation for survival remains a challenge, and strategies to overcome this are discussed. One GGTTI has recently entered the clinic, and the safety and efficacy of GGTTIs await results from clinical trials.

---

Interest in developing inhibitors of farnesylation as anticancer drugs was prompted by the realization more than 20 years ago that a sizable proportion of some, but not all, human cancers harbour activating oncogenic mutations in the *RAS* genes (between 8% and 93%, depending on the tumour type)<sup>1</sup>, and that *RAS* GTPases require this lipid post-translational modification (PTM) for their malignant transforming activity<sup>2</sup>. Furthermore, many of the signal transduction pathways that are activated by *RAS* involve proteins that require

---

Correspondence to: Saïd M. Sebti, [said.sebti@moffitt.org](mailto:said.sebti@moffitt.org).

#### Competing interests statement

The authors declare competing financial interests. See Web version for details.

#### DATABASES

ClinicalTrials.gov: <http://clinicaltrials.gov/>

National Cancer Institute Drug Dictionary: <http://www.cancer.gov/drugdictionary> 5-fluorouracil | BMS-214662 | bryostatin 1 | carboplatin | cisplatin | cyclophosphamide | doxorubicin | gemcitabine | imatinib | lonafarnib | paclitaxel | tipifarnib | triciribine phosphate | vincristine

UniProt: <http://www.uniprot.org/>

#### FURTHER INFORMATION

Saïd M. Sebti's homepage:

Catalogue of Somatic Mutations in Cancer (COSMIC): <http://www.sanger.ac.uk/cosmic>

PrePS – Prenylation Prediction Suite: <http://mendel.imp.ac.at/sat/PrePS/>

#### SUPPLEMENTARY INFORMATION

See online article: S1 (table) | S2 (table) | S3 (table) | S4 (table) | S5 (table) | S6 (figure)

farnesylation or geranylgeranylation (together referred to as prenylation) for their ability to mediate tumour cell survival, growth, proliferation, migration and metastasis (FIG. 1). This, coupled with the fact that it has notoriously been difficult to design small GTPase inhibitors per se<sup>3</sup>, prompted a global quest to develop farnesyltransferase (FT) inhibitors (FTIs) and geranylgeranyltransferase 1 (GGT1) inhibitors (GGTIs) (together referred to as prenyltransferase (PT) inhibitors (PTIs)) as potential anticancer drugs.

Preclinical studies in the 1990s demonstrated that FTIs are highly successful in killing cancer cells *in vitro* and in animals with very little toxicity, thus generating much excitement and raising the hope that, finally, a RAS inhibitor may be developed as a novel anticancer drug. Contrary to expectations, however, responses to FTIs, whether in cells, animals or human patients, do not seem to depend on RAS mutations; and the inhibition of KRAS farnesylation leads to its geranylgeranylation (discussed below). Furthermore, in most clinical trials FTIs have not been as successful as expected, with no survival advantages, for example, to patients with advanced solid cancers<sup>4-6</sup> or with acute myeloid leukaemia (AML)<sup>7</sup>. However, monotherapy with FTIs demonstrates antitumour activity in a subset of cancer patients, particularly those with haematological malignancies, whereas combinations of FTIs with cytotoxic agents improve the responses of patients with locally advanced breast cancer or other advanced solid tumours<sup>8-11</sup>. At present, we do not understand why some tumours are resistant while others are sensitive to FTIs. Clearly, the identification of the farnesylated proteins the inhibition of which is responsible for the antitumour effects of FTIs will lead to a better understanding of their mechanism of action and to the selection of patients whose tumours are sensitive to FTI treatment.

GGTIs as potential anticancer agents were developed for several reasons. First, KRAS (predominantly the alternatively spliced KRAS4B variant), which is the most frequently mutated isoform of RAS<sup>1</sup>, and NRAS become geranylgeranylated and remain fully functional when cells are treated with FTIs<sup>12-15</sup>. Second, in some human malignancies, such as pancreatic cancer with KRAS mutated in 90% of patients<sup>1</sup>, pathways that are mediated by geranylgeranylated proteins downstream of RAS, such as RALA and RALB, may be more relevant to oncogenesis than those mediated by MEK or AKT<sup>16,17</sup>. Third, the exclusively geranylgeranylated RHOC has an essential role in metastasis<sup>18,19</sup>. Fourth, the small GTPases cell division cycle 42 (CDC42) and RAC, which are exclusively geranylgeranylated, are crucial downstream targets for RAS-dependent transformation in rodent fibroblasts<sup>20,21</sup>. Furthermore, RAC1 is required to induce KRAS-driven lung cancer in mice<sup>22</sup>. Thus, GGTIs should be more efficient in cancer cells that are addicted to geranylgeranylated proteins, whereas FTI-GGTI combinations or dual prenylation inhibitors might be required to combat KRAS-dependent human tumours<sup>23</sup>. Similar to FTIs, GGTIs have shown promising results *in vitro* and in animal models, and one GGTI (GGTI-2418) has recently entered Phase I clinical trials<sup>24</sup>.

A better understanding of the aberrant signalling pathways that a given tumour is addicted to and the effects of PTIs on these pathways will lead to strategies that exploit the vulnerabilities of individual tumours and ultimately to predicting which patient populations are most likely to respond to PTIs, either alone or in combination. Work has begun in pursuing this goal with the identification of a two-gene expression ratio that potentially

predicts the response of patients with AML to the FTI tipifarnib (also known as R115777)<sup>25,26</sup> (discussed below).

## General aspects of protein prenylation

### The importance of FT and GGT1 for normal physiology and tumorigenesis: lessons from knockout mice

The biochemistry of prenylation and pioneering findings in the field of prenylation research are summarized in BOX 1 and the TIMELINE, respectively. Protein prenylation is required for the membrane localization of otherwise cytosolic proteins. Studies in yeast<sup>27</sup> and mammalian cells<sup>28</sup> suggest that protein prenylation is also required for the normal function of at least some proteins. Additionally, defective prenylation has been attributed to the pathogenesis of several diseases other than cancer (BOX 2) Contemporary reviews have estimated that several hundred proteins are subject to prenylation<sup>29,30</sup>. Therefore, the inhibition of FT activity probably prevents many proteins from functioning properly, and it is perhaps not surprising that genetic disruption of the catalytic FT  $\beta$ -subunit (*Fntb*) in mice causes embryos to die very early in development<sup>31</sup> (TABLE 1). Whether the constitutive ablation of GGT1 activity in mammals is also embryonically lethal has not yet been determined. However, studies conducted in *Saccharomyces cerevisiae*<sup>32</sup>, *Drosophila melanogaster*<sup>33</sup> and mouse embryonic fibroblasts<sup>34</sup>, as well as the fact that more proteins are geranylgeranylated than are farnesylated<sup>35</sup>, suggest that GGT1 function is essential for survival and development, and that the functions of FT and GGT1 are not redundant.

More interesting in this context are the results obtained with conditional FT deletions. The first such study by Barbacid and colleagues<sup>31</sup> suggested that FT is not required for tumour initiation in mice, either in mice developing KRAS-G12V-induced lung adenocarcinoma or in mice subjected to carcinogen-induced skin carcinoma, but that it is required for tumour progression and maintenance<sup>31</sup>. The study also suggested that adult mice lacking *Fntb* show normal tissue homeostasis except for slight defects in wound healing or liver regeneration. Finally, in these conditional FT-knockout mice, the authors suggested that wild-type HRAS still associates with cellular membranes<sup>31</sup>. Recently, these unexpected results have been called into question by Yang *et al.*<sup>36</sup> who re-analysed the conditional *Fntb*-null allele generated by the Barbacid laboratory: it produced a transcript that encoded a protein with a short in-frame deletion rather than, as expected, a transcript with a frameshift mutation that resulted in a true null allele. Thus, the results described above may have been due to a 'leaky' null allele that permitted the expression of partially active FT.

Two other recent studies by Bergo and colleagues have shown that conditional *Fntb* deficiency<sup>37</sup> or conditional *Pggt1b* (which encodes the catalytic  $\beta$ -subunit of GGT1) deficiency<sup>34</sup> reduces the formation of KRAS-G12D-induced lung cancer in mice. Furthermore, simultaneous knockout of both *Fntb* and *Pggt1b* has a far greater effect on KRAS-G12D-induced lung tumour onset and progression than either deletion alone<sup>37</sup>. Also, loss of both *Fntb* and *Pggt1b* significantly extends the lifespan of mice that express activated KRAS-G12D in their lungs, which validates FT and GGT1 as important targets for cancer therapy. In contrast to the earlier study by Barbacid *et al.*<sup>31</sup>, Bergo and colleagues

demonstrated that *Fntb* transcripts were not detectable, and HRAS does not associate with cell membranes in the absence of FT<sup>37</sup>, confirming earlier cell-based studies.

Bergo and colleagues have also recently described the effect of GGT1 deficiency in the haematopoietic system<sup>38</sup>. Mice harbouring an inducible *Kras*<sup>G12D</sup> oncogene in haematopoietic cells develop a lethal myeloproliferative disease (MPD), and up to one-third also develop acute lymphoblastic leukaemia (ALL). Whereas the absence of GGT1 markedly reduced the severity of MPD, it had no effect on ALL<sup>38</sup>. As KRAS can be farnesylated in the absence of GGT1, the antitumour effects of GGT1 depletion with regards to MPD can be attributed to defective prenylation of other GGT1 targets<sup>38</sup> that are downstream of KRAS, such as RALA and RALB.

### Regulation of PTs

Given the importance of PTs, it is surprising that their regulation in response to external signals has not been investigated in great detail. The  $\alpha$ -subunit of FT and GGT1, FNT $\alpha$ , has been shown to be phosphorylated in a transforming growth factor- $\beta$  (TGF $\beta$ )-dependent manner, which either does not affect<sup>39</sup> or decreases FT activity<sup>40</sup>. FNT $\beta$  was also shown to be phosphorylated<sup>41</sup>, raising the possibility that both of these events are necessary to modulate FT activity. Furthermore, insulin stimulates activating phosphorylation of FNT $\alpha$  by a member of the RAF1–MEK–MAPK pathway<sup>42</sup>.

FNT $\alpha$  is cleaved by caspase 3 during apoptosis<sup>43</sup>, suggesting that some signals may induce apoptosis by indirectly inhibiting the prenylation and the function of proteins that are involved in cell survival. Interestingly, dietary fish oil, which contains high levels of  $\Omega$ 3 polyunsaturated fatty acids, inhibits the expression of FT and colon tumorigenesis in rats<sup>44</sup>, which is consistent with the observation that FT activity is increased in human colon cancer<sup>45</sup>. These findings also raise the possibility that FTIs may function as chemopreventive agents, an idea that has received experimental support in mouse models of lung cancer<sup>46,47</sup>.

### Mechanism of action of FTIs

The observation that FT and GGT1 may be dispensable for adult tissue homeostasis, but may be required for KRAS-driven tumorigenesis<sup>34,37</sup>, further validated the concept of developing PTIs as novel anticancer drugs. Several strategies, including structure-based drug design and high-throughput screens, were used to identify a variety of PTIs (see Supplementary information S1 (table) for structures and potencies of representative compounds).

Depending on the context, the treatment of cancer cells with FTIs results in the induction of apoptosis, cell cycle arrest and the inhibition of anchorage-dependent and anchorage-independent cell proliferation, cell migration and angiogenesis (see Supplementary information S2 (table)). The exact mechanisms by which FTIs induce the antitumour effects described above are unknown mainly because the identity of the crucial farnesylated proteins, the inhibition of which mediates these FTI effects, is unknown (discussed further

below). However, several studies have shown that FTIs affect oncogenic and survival signal transduction pathways, which can explain some of their antitumour effects.

### Cell proliferation

FTIs inhibit signalling pathways that are involved in anchorage-dependent and anchorage-independent proliferation. In well-defined systems in which mutant HRAS drives the transformation of NIH3T3 cells, FTIs inhibit the farnesylation of HRAS, prevent its association with the plasma membrane, inhibit downstream signal transduction pathways such as RAF–MEK–MAPK<sup>48</sup> and inhibit tumour growth<sup>15</sup>. In human tumour cell lines with multiple genetic alterations, FTIs inhibit PI3K–AKT signalling, particularly in ovarian and pancreatic cancer cells that overexpress AKT2 (REF. 49), although this seems to be context-specific, as, in lung cancer cells with low or undetectable levels of phospho-AKT, lonafarnib (also known as SCH66336)-induced apoptosis does not rely on AKT inhibition<sup>50</sup>. In nude mice, many FTIs inhibit the growth of human tumours harbouring a variety of genetic alterations, including *KRAS* mutations, *TP53* deletions and silenced cyclin-dependent kinase inhibitor 2A (*CDKN2A<sup>INK4A</sup>*)<sup>51</sup>. Similarly, in transgenic mice that express mutant *KRAS* or that overexpress wild-type *NRAS*, FTIs only inhibit tumour growth and do not induce tumour regression<sup>52,53</sup>. However, in mutant *Hras*-transgenic mice, FTIs cause tumour regression (see below) (see Supplementary information S3 (table)).

### Cell cycle progression

FTIs primarily accumulate cells at prometaphase by preventing bipolar spindle formation and chromosome alignment<sup>54,55</sup>, which may rely on the inhibition of the farnesylation of the centromere-associated protein E (CENPE) and CENPF<sup>56,57</sup>, as well as phosphatase of regenerating liver (PRL) protein tyrosine phosphatases (PTPs)<sup>58</sup>. However, in some human cancer cell lines FTIs can induce G1 phase arrest. For example, L-744,832 induces p21 accumulation and inhibition of RB phosphorylation<sup>59</sup>. Similarly, in Rat1 fibroblasts transformed with HRAS<sup>G12V</sup>, the FTI HR-12 causes the accumulation of p27, which results in the inhibition of cyclin-dependent kinase 2 (CDK2) and subsequent G1 arrest<sup>60</sup>. This compound inhibits both anchorage-dependent and anchorage-independent cell growth and blocks cell motility in wound healing assays. Rat1 cells transformed with myristoylated HRAS<sup>G12V</sup> are resistant to HR-12 (REF. 60), indicating that the inhibition of HRAS farnesylation is responsible for HR-12 effects.

### Apoptosis

FTIs cause breast tumour regression very effectively in mutant *Hras*-transgenic mice<sup>61</sup> that express *Myc* or that lack *Trp53*, but not in *ErbB2*-transgenic mice<sup>62</sup>, suggesting that these drugs may induce apoptosis, which was confirmed by studies in cultured cells. For example, FTIs inhibit integrin-mediated and growth factor-mediated activation of the PI3K–AKT pathway, which results in the dephosphorylation of AKT substrates, including the pro-apoptotic BCL-2 family member BCL-2 antagonist of cell death (BAD), which leads to its activation. In this setting, overexpression of constitutively active AKT2 rescues FTI-induced apoptosis<sup>49</sup>. However, in other cells, FTIs induce apoptosis only when deprived of growth factors or of substratum attachment, suggesting that growth factors and integrins can rescue

FTI-induced apoptosis<sup>63–65</sup>. FTIs can also induce apoptosis by enhancing death receptor signals<sup>66</sup> or by inhibiting nuclear factor- $\kappa$ B (NF- $\kappa$ B)-dependent induction of cyclin D1, survivin, inhibitor of apoptosis proteins (IAPs) and BCL-2 (REF. 67). Another FTI that has been explored in preclinical and clinical studies, BMS-214662, has pro-apoptotic activity and induces tumour regression in nude mouse xenografts, but this seems to be related to the inhibition of GGT2 and not FT or GGT1 (REF. 68).

## Angiogenesis

Lonafarnib inhibits angiogenesis in lung and head and neck tumour cells by decreasing hypoxia and insulin-like growth factor 1 (IGF1)-stimulated hypoxia inducible factor 1 $\alpha$  (HIF1 $\alpha$ ) expression<sup>69</sup>. This study also showed that lonafarnib inhibits vascular endothelial growth factor A (VEGFA) production by inhibiting HIF1 $\alpha$  binding to heat shock protein 90 (HSP90), which results in the degradation of HIF1 $\alpha$ . Consistent with this, other FTIs, such as L-744,832 (REF. 70) and tipifarnib<sup>71</sup>, affect angiogenesis, possibly by inhibiting HIF1 $\alpha$  expression and hypoxia. Finally, another FTI, LB42708, inhibits angiogenesis, possibly by inhibiting pathways that are mediated by MAPK and AKT<sup>72</sup>.

## Combinations

In cell culture, structurally unrelated FTIs can enhance the growth inhibitory and apoptotic effects of radiation<sup>73</sup>, taxanes<sup>74,75</sup>, cisplatin<sup>76,77</sup>, 5-fluorouracil<sup>78</sup>, MEK inhibitors<sup>79</sup>, CDK inhibitors<sup>80</sup> and the breakpoint cluster region (BCR)–ABL inhibitor imatinib (also known as STI-571)<sup>81</sup>. In nude mouse xenografts, beneficial combinations have been reported for lonafarnib and cytotoxic agents such as cyclophosphamide, 5-fluorouracil, vincristine<sup>82</sup> and paclitaxel<sup>83</sup>, or for FTI-2148 and paclitaxel, cisplatin and gemcitabine<sup>84</sup>. We have recently found that a combination of tipifarnib and the inhibitor of AKT activation triciribine phosphate (TCNP)<sup>85</sup> (but not the single agents alone) causes breast tumour regression in *ErbB2*-transgenic mice<sup>86</sup>.

Several studies by Giannakakou and colleagues have recently provided a mechanistic explanation for the commonly observed synergy between FTIs and taxanes. First, they showed that lonafarnib in combination with paclitaxel enhances tubulin acetylation more than the effect of either drug alone, and that this is due to the inhibition of histone deacetylase 6 (HDAC6)<sup>87</sup>, an enzyme that functions as a tubulin deacetylase and that is involved in stress response, microtubule stability and cell migration. FTIs increase the amount of microtubule-bound paclitaxel, even in cells that are resistant to paclitaxel alone, and this is dependent on functional HDAC6 (REF. 88). Finally, FT and HDAC6 physically associate with each other at microtubules, and FTIs induce the dissociation of FT from microtubules, resulting in the inhibition of HDAC6 activity, an effect that was duplicated by stable knockdown of FNT $\alpha$  using short hairpin RNA (shRNA)<sup>89</sup>. Most interestingly, HDAC6 does not contain a carboxy-terminal CaaX motif and is thus a very unlikely FT substrate. It is possible that other FT targets that are present in the microtubule–protein complex mediate FT regulation of HDAC6.

### GGTI effects in cultured cells and *in vivo*

Similar to FTIs, GGTTs induce apoptosis and inhibit tumour cell growth, both in cultured cells and in animal models (see Supplementary information S3 (table)). In contrast to FTIs, GGTTs result in G1 arrest and not mitotic arrest<sup>90</sup>. Their ability to induce G1 arrest may be due to inducing the expression of the CDK inhibitors p21 and p27, inhibition of CDK2 and CDK4, and hypophosphorylation of RB<sup>91</sup>. GGTTs induce the accumulation of p27 in the nucleus through the inhibition of CDK2-mediated phosphorylation of Thr187 in p27, and this is important for their ability to induce tumour cell death<sup>92</sup>. Tamanoi and colleagues recently described P61-A6, a GGTT that causes G1 arrest, probably (at least in part) by inhibiting RHOA geranylgeranylation and inducing p21 expression (REFS 93,94). Furthermore, GGTT-induced apoptosis may also depend on their ability to reduce the levels of phosphorylated and thus activated AKT and survivin<sup>95</sup>. GGTTs can also induce apoptosis by increasing death receptor 5 (DR5; also known as TNFRSF10B) expression, decreasing cellular FLICE-like inhibitory protein (cFLIP; also known as CFLAR) expression and enhancing TNF-related apoptosis-inducing ligand (TRAIL)-induced apoptosis in human non-small-cell lung cancer (NSCLC) cells<sup>96</sup>. In addition, GGTTs inhibit platelet-derived growth factor (PDGF)-stimulation of PDGF receptor (PDGFR)-mediated tyrosine phosphorylation and MAPK signalling, suggesting that PDGFR phosphorylation is mediated by a GGTT1 substrate<sup>97</sup>.

The ability of our lead GGTT, GGTT-2418 (currently in Phase I clinical trials), to inhibit anchorage-dependent and anchorage-independent growth may also depend on its ability to inhibit the geranylgeranylation of RALB or RALA, respectively<sup>98</sup>. In addition, GGTT-2418 effectively prevents xenograft tumour growth in nude mice and results in breast tumour regression in *ErbB2*-transgenic mice<sup>92</sup>. Casey and colleagues described GGTT-DU40 (REF. 99), which is a highly potent and selective GGTT1 inhibitor that inhibits the prenylation of several cellular proteins, including RHO GTPases. In MDA-MB-231 breast cancer cells, GGTT-DU40, but not the FTI L-744,832, inhibits thrombin-induced cell rounding. GGTTs with novel scaffolds were recently identified by a virtual screen of 9.5 million compounds in conjunction with quantitative structure–activity relationship modelling<sup>100</sup>.

### FTIs in the clinic

Starting in 2000 (REF. 101), four FTIs have been evaluated in at least 75 clinical trials: tipifarnib, lonafarnib, BMS-214662 and L-778123. In 64 of these studies (with 35 being Phase I trials), the clinical response has been determined (TABLES 2,3; see Supplementary information S4 and S5 (tables)). Sixteen years after curing transgenic mice that developed mouse mammary tumour virus (*MMTV*)–*Hras*-driven breast tumours with FTIs<sup>61</sup>, and after accumulating other very impressive preclinical data, it has become clear that in human clinical trials, monotherapy with FTIs shows limited antitumour activity in haematopoietic cancers, and generally no or very little activity in solid tumours. Thirty-eight of the 64 clinical trials (59%) concerned tipifarnib, either alone or in combination with other agents. Eighteen of the 64 trials (28%) — all but one of which was conducted in patients with solid tumours — reported no objective responses. Seventeen of the 18 trials (94%) with no objective responses were conducted with FTI monotherapy. Twenty-three of the 64 trials

(36%) conducted in both solid and haematological malignancies showed very little antitumour activity (the rate of objective responses was <15%). The median objective response was 2.3% for monotherapy with FTIs and 11.4% for combinations with FTIs. Furthermore, in 28 of the 64 trials (44%), FT activity or the prenylation status of marker proteins (most commonly HDJ2 (also known as DNAJA1) or prelamin A) was assessed to determine whether the FTI treatment had affected its intended targets. There was no correlation between FT inhibition and clinical responses. Most importantly, two FTIs that have so far advanced to Phase III clinical trials are lonafarnib<sup>6</sup> and tipifarnib<sup>4,5,7</sup>, and, unfortunately, these drugs were unable to improve the outcome for advanced pancreatic cancer<sup>4</sup>, advanced colon cancer<sup>5</sup>, advanced NSCLC<sup>6</sup> or AML<sup>7</sup>, whether alone<sup>7,5</sup> or in combination with carboplatin and paclitaxel<sup>6</sup> or with gemcitabine<sup>4</sup>.

What accounts for this discrepancy between laboratory findings and clinical data? First, in humans, KRAS, and not HRAS, is most frequently mutated<sup>1</sup>. Second, unlike HRAS, which is exclusively farnesylated, KRAS (and possibly NRAS) can escape FTI-mediated inhibition as it can be alternatively prenylated by GGT1 and thus is fully functional<sup>12–15</sup> (BOX 1). Third, the lack of antitumour activity may be due to the fact that most of the clinical trials enrolled patients with advanced and/or metastatic disease. It is also important to note that even though it was known preclinically that KRAS function is resistant to FTIs, Phase III clinical trials were carried out in patients whose tumours harboured mutant KRAS (that is, patients with pancreatic cancer). Perhaps this is because preclinical studies had shown that some cancer cells that harbour mutant KRAS are sensitive to FTIs, possibly owing to the inhibition of exclusively farnesylated proteins downstream of KRAS. In another clinical trial, attempts were made to directly inhibit KRAS function by using L-778123, which inhibits both FT (half-maximal inhibitory concentration (IC<sub>50</sub>) = 2 nM) and GGT1 (IC<sub>50</sub> = 98 nM). Unfortunately, in peripheral blood mononuclear cells from patients treated with this drug, KRAS prenylation was not inhibited<sup>102</sup>.

When used in combination with other agents, FTIs have fared better. For example, Phase I studies based on a combination of tipifarnib with gemcitabine and cisplatin have shown some promise in advanced solid tumours (33.3% complete response rate or 26% partial response rate)<sup>8,9</sup>. Similarly, in Phase II neoadjuvant settings, tipifarnib increases the rate of pathological complete responses from the historical 10% to 25% when combined with chemotherapy (doxorubicin and cyclophosphamide) in patients with locally advanced breast cancer<sup>10,11</sup>. The fact that some patients respond to FTIs suggests that some human tumours depend on farnesylated proteins for survival. The identification of these proteins remains a challenge that must be overcome in order to select patients whose tumours are most likely to respond to FTIs. To this end, a strategy to predict clinical response to FTIs was recently developed by Raponi *et al.* Following the analysis of gene expression profiles from patients with untreated AML, these authors found that a high ratio of expression of two genes, RAS guanyl releasing protein 1 (*RASGRP1*), which encodes a RAS guanine nucleotide exchange factor (GEF) that activates RAS, and aprataxin (*APTX*), which encodes a protein involved in DNA excision repair, predicts a tipifarnib-positive response of patients with AML<sup>25,26</sup>. Moreover, in patients with advanced solid cancers, low mRNA levels of *FNTB*, but not



*FNTA*, are associated with improved response to lonafarnib plus taxane and significantly better survival<sup>103</sup>. Similar studies are needed for other types of cancer.

## Targets crucial for the antitumour activity of FTIs

As the data described above have illustrated, and as can be expected of drugs that affect a large number of PT substrates, PTIs trigger a plethora of molecular and cellular effects, whether in cell culture, animal models or in human cancer patients. A key question is, what are the crucial PT substrates that mediate these effects? The answer to this question may uncover why FTIs and GGTIs are only effective in a subset of cells and tumours.

### RAS proteins as crucial targets for FTIs

FTIs were originally developed to inhibit RAS function. However, the ability of FTIs to inhibit tumour growth is not correlated with mutations in RAS, whether in cells<sup>104,105</sup>, animals<sup>105</sup> or human patients<sup>106</sup> (discussed above). KRAS, the most frequently mutated human oncoprotein, becomes geranylgeranylated and is fully functional in tumour cells treated with FTIs<sup>12–15</sup>. However, FTIs are effective at inhibiting the growth of mutant KRAS-harboured tumours in nude mice<sup>107</sup> and transgenic mouse models<sup>53</sup>, suggesting that the inhibition of KRAS farnesylation is not required for FTI antitumour activity, and that, in these models, tumours are addicted to farnesylated proteins other than KRAS. Similar considerations apply to NRAS, because it can also escape FTI-mediated inhibition. HRAS, conversely, is not alternatively geranylgeranylated in cells treated with FTIs. Therefore, the inhibition of HRAS farnesylation can still contribute to FTI antitumour activity in tumours that are addicted to mutant or wild-type HRAS for survival. Thus, it may be worthwhile to design clinical trials that involve FTIs for patients with *HRAS*-mutant bladder cancers, a tumour that has clearly been understudied so far (TABLES 2,3).

### RHEB as a crucial target for FTIs

Like HRAS, RAS homologue enriched in brain (RHEB) is exclusively farnesylated<sup>75</sup>. The GTPase-activating protein (GAP) for RHEB is the tumour suppressor tuberous sclerosis complex TSC1–TSC2 (REFS 108–110). AKT phosphorylates and inactivates TSC1–TSC2, causing activation of RHEB<sup>111–113</sup>. RHEB stimulates the protein kinase mTOR, which results in activating phosphorylation of the mTOR substrates S6 kinase (S6K) and eukaryotic translation initiation factor 4E-binding protein 1 (4EBP1)<sup>114,115</sup>, which is consistent with RHEB being essential for cell growth and cell cycle progression in *D. melanogaster*<sup>116</sup>. RHEB may activate mTOR either by directly binding to it<sup>117</sup> or by binding to the mTOR antagonist FKBP38 (also known as FKBP8)<sup>118</sup>. Most importantly, the ability of RHEB to stimulate mTOR depends on its farnesylation<sup>75,114</sup>. Therefore, cancer cells that are addicted to RHEB may be sensitive to FTIs. For example, this could include tumours that overexpress RHEB or that harbour persistently activated pathways that lead to constitutive RHEB activation (including, PTEN deficiency, PI3K and AKT mutations, AKT overexpression or TSC1–TSC2 deficiency). Consistent with this idea, RHEB is frequently upregulated in transformed cells and human cancer cells<sup>75,119</sup>, and, in several NSCLC cell lines, the ability of FTIs to inhibit proliferation or induce apoptosis depends on RHEB expression levels, which in turn are correlated to the degree of S6K phosphorylation by

mTOR<sup>77</sup>. Similarly, RHEB is overexpressed in some lymphomas, which have increased mTOR activity and enhanced sensitivity to FTIs<sup>120</sup>. The fact that an exclusively geranylgeranylated mutant of RHEB (RHEB-GG) renders PTEN-deficient lymphoma cells resistant to FTIs further supports the idea that the inhibition of RHEB farnesylation contributes to the antitumour activity of FTIs<sup>120</sup>. Similar results were obtained when RHEB-GG was shown to rescue the ability of FTIs to synergize with paclitaxel<sup>75</sup> and cisplatin<sup>77</sup>. As mTOR is an inhibitor of autophagy<sup>121</sup>, and RHEB activates mTOR, it may not be surprising that FTIs can induce autophagy, possibly by blocking RHEB function<sup>122</sup>. The induction of autophagy may be particularly important in cancer cells that are resistant to apoptosis. Collectively, these findings suggest that the inhibition of RHEB farnesylation contributes to the antitumour activity of FTIs, which should perhaps be evaluated in clinical trials for patients with tumours that express high levels of RHEB, as well as for patients with tuberous sclerosis, which is a syndrome caused by the loss of TSC1 or TSC2 function.

### **Inhibition of RHOB farnesylation is unlikely to contribute to the antitumour activity of FTIs**

Under physiological conditions, RHOB is found both geranylgeranylated (RHOB-GG), which accounts for 70% of all RHOB, and farnesylated (RHOB-F), which accounts for the remaining 30%, in cells. It has been suggested that the inhibition of RHOB farnesylation accumulates RHOB-GG and contributes to FTI-induced apoptosis<sup>123,124</sup>. Consistent with this, in murine fibroblasts, RHOB-GG but not RHOB-F, suppresses RAS-induced transformation<sup>125</sup>. However, the fact that a large proportion of RHOB is already in the geranylgeranylated form in the absence of FTI treatment argues against a major contribution of inhibition of RHOB farnesylation to FTI antitumour activity. More importantly, in human cancer cells of epithelial origin, both RHOB-F and RHOB-GG have tumour suppressive activity, further arguing against the inhibition of RHOB farnesylation playing a part in FTI antitumour activity<sup>126</sup>. Consistent with RHOB functioning as a tumour suppressor, RHOB is downregulated in several human cancers<sup>127–129</sup>. Although RHOB was shown to be farnesylated *in vitro* by FT, and the treatment of cultured cells with the FTI L-739749 increases the levels of RHOB-GG<sup>130</sup>, the laboratory of Goldstein and Brown has shown using purified components that RHOB is farnesylated by GGT1 but not by FT<sup>131</sup>. This, of course, would disqualify RHOB as a target.

However, FTI treatment activates the *RHOB* promoter and accumulates large amounts of the RHOB protein<sup>132</sup>. Furthermore, mutant HRAS-transformed *RHOB*<sup>-/-</sup> cells are less sensitive to FTI-induced apoptosis and FTI inhibition of anchorage-dependent but not anchorage-independent tumour growth. Taken together, these results suggest that increased RHOB protein levels, not inhibition of RHOB farnesylation, may contribute to some of the effects of FTIs<sup>133</sup>.

### **Other possible targets**

FTIs are bound to have effects not only on oncogenic RAS family members, but also on other prenylated proteins some of which are not yet known. Some candidate targets for prenylation include tumour suppressors, ARHI (also known as NOEY2 and DIRAS3)<sup>134</sup>, RAS-related and oestrogen-regulated growth inhibitor (RERG)<sup>135</sup>, deleted in breast cancer 2 (DBC2; also known as RHOBTB2)<sup>136</sup>, RAS-related inhibitor of cell growth (RIG)<sup>137</sup>, RAS-

related protein on chromosome 22 (RRP22; also known as RASL10A)<sup>138</sup> and maybe others. The non-discriminatory action of PTIs may abrogate crucially important tumour suppressor functions and may at least partially compromise their effects on oncogenic pathways. Therefore, it needs to be established whether the proteins mentioned above are exclusively farnesylated or geranylgeranylated, and whether their prenylation is crucial to their growth inhibitory function. For proteins that pass these tests it is recommended that their functional status is assessed in future clinical trials.

The inhibition of the farnesylation of several other proteins could contribute to the antitumour activity of FTIs. These include CENPE, CENPF, the PRL phosphatases PRL1 (also known as PTP4A1), PRL2 (also known as PTP4A2) and PRL3 (also known as PTP4A3), lamins A and B, HDJ2, RND3, peroxisomal biogenesis factor 19 (PEX19), RHOD, RHO6, RHO7 (also known as RHON), TC10 (also known as RHOQ) and prostacyclin receptor (PTGIR). Although some of these may be associated with known effects of FTIs such as the possible role that CENPE and CENPF and PRLs may have in FTI-induced mitotic arrest, the contributions of others require further investigations.

## Alternative approaches

### RCE1 and ICMT inhibitors

Interestingly, prenylation seems to be constitutive, but prenylated proteins can undergo up to three additional PTMs, the last two of which are reversible (BOX 1). First, the last three C-terminal amino acids, aaX, are proteolytically removed by RAS-converting enzyme 1 (RCE1)<sup>139</sup>. Second, the carboxyl group in the now C-terminal prenylated cysteine is methylated by isoprenylcysteine carboxyl methyltransferase (ICMT)<sup>140</sup>. Third, many prenylated proteins become palmitoylated on upstream cysteines by membrane-bound palmitoyl transferases<sup>141</sup>. The carboxymethylation, which neutralizes the carboxyl negative charge, coupled with the palmitoylation, further stabilizes membrane association and anchoring.

RCE1 and ICMT, which function downstream of PTs, have also attracted attention as potential targets for cancer therapy. Conditional lack of *Rce1* expression in skin carcinoma cells that express activated HRAS has much less severe effects on cell proliferation than the effect of lonafarnib<sup>142</sup>. By contrast, conditional deletion of *Icmt* efficiently blocks transformation by either human KRAS-G12V or human BRAF-V599E oncogenic mutants<sup>140</sup>. Considering these results, ICMT inhibitors are more likely to be successful than RCE1 inhibitors. Indeed, pharmacological inhibition of ICMT inhibits the growth of HepG2 tumour xenografts in nude mice<sup>143</sup>. As postprenylation inhibitors will affect both farnesylated and geranylgeranylated proteins, these drugs may be more toxic than FTIs or GGTIs.

### Prenylated proteins that are phosphorylated

Several small GTPases are subject to reversible phosphorylation. For example, protein kinase C (PKC)- or PKA-mediated phosphorylation of CDC42, KRAS, RAP1A and RHOA induces their removal from the cell membrane<sup>144–147</sup>. The question is whether this relocation translates into a loss or change of function. With regard to KRAS, this has

recently been investigated. Interestingly, PKC-mediated phosphorylation of Ser181 in KRAS promotes its relocation to mitochondrial membranes where it associates with BCL-X<sub>L</sub> (also known as BCL2L1) and promotes apoptosis. Overexpression of KRAS-S181E is sufficient to induce apoptosis, an effect that is rescued by co-transfection with BCL-2 (REF. 145). This raises the intriguing possibility that PKC agonists such as bryostatin 1<sup>145</sup> may be more efficient for killing and/or less toxic to KRAS-dependent tumours than PTIs. Phosphorylation of RAB6, RHOE and RALA activates their function<sup>148–151</sup>. Most interestingly, aurora kinase A enhances, and protein phosphatase 2A (PP2A) inhibits, the transforming activity of RALA<sup>150,151</sup>. Provided that activating phosphorylation can occur independently of prenylation, these findings may indicate that GGTI-mediated inhibition of RALA may not be sufficient to completely block its transforming ability. However, these findings also suggest that GGTIs that inhibit RALA might synergize with aurora kinase A inhibitors or with PP2A agonists. Phosphorylation of CDC42, RHOB and RHEB inhibits their function<sup>152–154</sup>, cautioning against combinations of PTIs and protein kinase inhibitors to target CDC42- or RHEB-dependent tumours.

### Synthetic lethality

As is well documented, many human cancers depend on oncogenic KRAS for survival, and this dependency confers a vulnerability that is unique to these cancer cells. Indeed, recent unbiased RNA interference-based screens<sup>155–159</sup> and other approaches<sup>160</sup> identified six genes the knockdown of which kills only human tumours that depend on mutant KRAS. Such a synthetically lethal strategy would be of benefit if some of the identified targets are more druggable than KRAS (see Supplementary information S6 (figure)). Of the six studies cited above, the one identifying the lethal interaction between oncogenic KRAS and CDK4 is particularly interesting<sup>160</sup>. It has been previously reported that RAS-mediated transformation requires the expression of functional RB in mouse fibroblasts<sup>161</sup>. This is consistent with the fact that activated RAS induces cyclin D1 (REF. 162), which activates CDK4 and other kinases and ultimately leads to inhibitory phosphorylation of RB, thus permitting the G1/S transition<sup>163</sup>. These considerations might explain why human tumours very rarely display loss-of-function mutations in RB together with activating RAS mutations<sup>164</sup>. Furthermore, they provide a rationale for investigating whether PTIs and CDK inhibitors act in a synergistic fashion, both in animals and in clinical trials.

Considering the enormous number of proteins affected by the RAS signalling network, we predict that further synthetic lethal interactions will be identified. For example, small interfering RNA (siRNA) screens silencing protein kinases or protein phosphatases may reveal molecular targets the inhibition of which sensitizes cancer cells to PTIs. Conversely, siRNA screens silencing the prenylome may reveal crucial prenylated proteins the inhibition of which sensitizes cancer cells to drugs that target other signal transduction pathways; for example, PI3K–AKT, RAF–MEK–MAPK and CDKs.

### Future directions and challenges

Despite the conceptual advances that have been made over the past decade, in our opinion, the major challenge in this field is the following question: which PT substrates are crucial for the proliferation or survival of different cancer types? Or, in other words, does the

antitumour activity of PTIs in a given tumour depend on the inhibition of certain prenylated proteins? At present, the exact size of the prenylome is unknown<sup>165</sup>. Although more than 100 proteins have been experimentally confirmed to undergo prenylation<sup>166</sup>, a recent search of the UniProt database (release 20 April 2010; see Further information) returned 587 human genes that encode proteins bearing a C-terminal CXXX motif. Although not all of these proteins will qualify as PT substrates, this suggests that many prenylated proteins have not yet been identified.

Current standard methods to characterize protein prenylation are, for the most part, designed to follow individual proteins<sup>167</sup> and are thus not practical to address the above questions. Therefore, this field should develop and streamline techniques that are capable of analysing prenylation on a global scale, in a manner that is reasonably rapid, feasible and convenient for many laboratories. As a step towards characterizing the entire prenylome, Maurer-Stroh *et al.*<sup>165</sup> have recently developed a sequence-based software suite that is designed to predict whether proteins hitherto unknown to be prenylated are likely to be modified by FT, GGT1 and/or GGT2. Combining this with approaches that uncover actual prenylation patterns in various cancer cells, as well as changes in prenylation patterns in response to PTIs, will eventually reveal which prenylated proteins the inhibition of which is responsible for the antitumour effects of PTIs and which patients are most likely to respond to treatment with these inhibitors. Several techniques pursuing this goal have recently been described<sup>168–173</sup>. For example, labelling cells with modified tractable prenyl donors in lieu of the natural farnesyl diphosphate (FPP) or geranylgeranyl diphosphate (GGPP) is a step in that direction. This can involve the labelling of cells with azido-farnesyl, followed by the affinity purification of farnesylated proteins with a biotinylated phosphine capture reagent<sup>168</sup>. Similarly, labelling cells with azido-GG analogues, followed by the selective labelling of the resulting azido-GG proteins with a modified rhodamine, can be used to detect geranylgeranylated proteins by fluorescent imaging<sup>172</sup>.

It is our belief that proteome-wide or prenylome-wide approaches, such as those discussed above, are urgently needed to identify the subsets of prenylated proteins that are affected by FTIs and/or GGTIs, which in turn should help to link the physiological effects of various PTIs to their molecular targets, and thus will help to design improved clinical trials.

## Supplementary Material

Refer to Web version on PubMed Central for supplementary material.

## Acknowledgments

This work was partially supported by US National Institutes of Health grants CA067771 and CA098473 to S.M.S.

## Glossary

|                      |   |
|----------------------|---|
| <b>Farnesylation</b> | One of two types of prenylation. This involves the transfer of a farnesyl moiety to the cysteine of the C-terminal CaaX box of the target protein. Catalysed by farnesyltransferase |
|----------------------|---|

|                            |  |
|----------------------------|--|
| <b>Geranylgeranylation</b> | This prenylation is catalysed by geranylgeranyltransferase 1 (GGT1) or GGT2. GGT1 transfers a geranylgeranyl moiety to the cysteine of the C-terminal CaaX box, and GGT2 acts on the cysteines of C-terminal CXC or CC motifs  |
| <b>Prenylation</b>         | Also known as isoprenylation. An irreversible post-translational modification of proteins consisting of the covalent attachment of an isoprenyl lipid to a cysteine within four residues of the C terminus   |
| <b>Myristoylated</b>       | A universal and irreversible co-translational modification of proteins involving the covalent attachment of a myristoyl group to an N-terminal amino acid of a nascent polypeptide. It is important for membrane targeting of the modified protein   |
| <b>CaaX motif</b>          | This refers to the last four C-terminal amino acids that serve as a recognition motif for farnesyltransferase or geranylgeranyltransferase 1. C (cysteine) is the amino acid being modified, a is an aliphatic residue and X is any residue  |
| <b>Intimal hyperplasia</b> | The thickening of the innermost layer of a blood vessel as a complication of a reconstruction procedure or endarterectomy. It is the universal response of a vessel to injury and is an important reason for late bypass graft failure, particularly in vein and synthetic vascular grafts |
| <b>Neointima</b>           | A new or thickened layer of arterial intima (innermost layer of an artery or a vein) formed especially on a prosthesis or in atherosclerosis by migration and proliferation of cells from the media  |
| <b>Palmitoylated</b>       | A post-translational modification, consisting of the covalent attachment of fatty acids to cysteine residues of membrane proteins, thought to further enhance membrane anchoring of previously prenylated proteins. In contrast to prenylation and myristoylation, it is reversible        |
| <b>Prenylome</b>           | The subset of proteins in a cell or organism that is modified by prenylation   |

## References

1. Bos JL. ras oncogenes in human cancer: a review. *Cancer Res.* 1989; 49:4682–4689. [PubMed: 2547513]
2. Jackson JH, et al. Farnesol modification of Kirstenras exon 4B protein is essential for transformation. *Proc Natl Acad Sci USA.* 1990; 87:3042–3046. [PubMed: 2183224]
3. Bommi-Reddy A, Kaelin WG. Slaying RAS with a synthetic lethal weapon. *Cell Res.* 2010; 20:119–121. [PubMed: 20118966]
4. Van Cutsem E, et al. Phase III trial of gemcitabine plus tipifarnib compared with gemcitabine plus placebo in advanced pancreatic cancer. *J Clin Oncol.* 2004; 22:1430–1438. [PubMed: 15084616]

5. Rao S, et al. Phase III double-blind placebo-controlled study of farnesyl transferase inhibitor R115777 in patients with refractory advanced colorectal cancer. *J Clin Oncol.* 2004; 22:3950–3957. [PubMed: 15459217]
6. Blumenschein G, et al. A randomized phase III trial comparing lonafarnib/carboplatin/paclitaxel versus carboplatin/paclitaxel (CP) in chemotherapy-naïve patients with advanced or metastatic non-small cell lung cancer. *Lung Cancer.* 2005; 49:S30.
7. Harousseau JL, et al. A randomized phase 3 study of tipifarnib compared with best supportive care, including hydroxyurea, in the treatment of newly diagnosed acute myeloid leukemia in patients 70 years or older. *Blood.* 2009; 114:1166–1173. References 4–7 describe the results of Phase III clinical trials with lonafarnib or tipifarnib. Whether alone or in combination the FTIs failed to even slightly improve the outcome for patients with advanced NSCLC, advanced pancreatic cancer, advanced colon cancer or AML. [PubMed: 19470696]
8. Adjei AA, et al. A Phase I trial of the farnesyl protein transferase inhibitor R115777 in combination with gemcitabine and cisplatin in patients with advanced cancer. *Clin Cancer Res.* 2003; 9:2520–2526. [PubMed: 12855626]
9. Siegel-Lakhai WS, et al. Phase I and pharmacological study of the farnesyltransferase inhibitor tipifarnib (Zarnestra, R115777) in combination with gemcitabine and cisplatin in patients with advanced solid tumours. *Br J Cancer.* 2005; 93:1222–1229. [PubMed: 16251868]
10. Sparano JA, et al. Targeted inhibition of farnesyltransferase in locally advanced breast cancer: a phase I and II trial of tipifarnib plus dose-dense doxorubicin and cyclophosphamide. *J Clin Oncol.* 2006; 24:3013–3018. [PubMed: 16769985]
11. Sparano JA, et al. Phase II trial of tipifarnib plus neoadjuvant doxorubicin-cyclophosphamide in patients with clinical stage IIB–IIIC breast cancer. *Clin Cancer Res.* 2009; 15:2942–2948. References 8–11 stand out from the bulk of clinical trials with FTIs in that they demonstrate that a combination of tipifarnib with chemotherapy can make a difference, even in solid advanced tumours. [PubMed: 19351752]
12. Rowell CA, Kowalczyk JJ, Lewis MD, Garcia AM. Direct demonstration of geranylgeranylation and farnesylation of Ki-Ras *in vivo*. *J Biol Chem.* 1997; 272:14093–14097. [PubMed: 9162034]
13. Whyte DB, et al. K- and N-Ras are geranylgeranylated in cells treated with farnesyl protein transferase inhibitors. *J Biol Chem.* 1997; 272:14459–14464. [PubMed: 9162087]
14. Lerner EC, et al. Inhibition of the prenylation of K-Ras, but not H- or N-Ras, is highly resistant to CAAX peptidomimetics and requires both a farnesyltransferase and a geranylgeranyltransferase I inhibitor in human tumor cell lines. *Oncogene.* 1997; 15:1283–1288. [PubMed: 9315095]
15. Sun J, Qian Y, Hamilton AD, Sebti SM. Both farnesyltransferase and geranylgeranyltransferase I inhibitors are required for inhibition of oncogenic K-Ras prenylation but each alone is sufficient to suppress human tumor growth in nude mouse xenografts. *Oncogene.* 1998; 16:1467–1473. References 12–15 by three independent groups show that KRAS can escape FTI-mediated inhibition and remain fully functional through undergoing cross-prenylation by GGT1. As *KRAS* is the most frequently mutated human oncogene, this finding was disappointing as it meant that *KRAS* function could not be inhibited with FTIs. [PubMed: 9525745]
16. Hamad NM, et al. Distinct requirements for Ras oncogenesis in human versus mouse cells. *Genes Dev.* 2002; 16:2045–2057. [PubMed: 12183360]
17. Lim KH, et al. Activation of RalA is critical for Ras-induced tumorigenesis of human cells. *Cancer Cell.* 2005; 7:533–545. References 16 and 17 show that exclusively geranylgeranylated RALA and RALB, which are downstream of RAS, may be more important for some human cancers than the RAF–MEK–ERK or PI3K–AKT pathways. [PubMed: 15950903]
18. Clark EA, Golub TR, Lander ES, Hynes RO. Genomic analysis of metastasis reveals an essential role for RhoC. *Nature.* 2000; 406:532–535. [PubMed: 10952316]
19. Hakem A, et al. RhoC is dispensable for embryogenesis and tumor initiation but essential for metastasis. *Genes Dev.* 2005; 19:1974–1979. References 18 and 19 provide evidence that the exclusively geranylgeranylated RHOC is not necessary for embryonic development but is essential for metastasis. These results, together with those of references 16 and 17, can be regarded as a major incentive for developing GGTIs to treat advanced cancers. [PubMed: 16107613]
20. Qiu RG, Abo A, McCormick F, Symons M. Cdc42 regulates anchorage-independent growth and is necessary for Ras transformation. *Mol Cell Biol.* 1997; 17:3449–3458. [PubMed: 9154844]

21. Joyce PL, Cox AD. Rac1 and Rac3 are targets for geranylgeranyltransferase I inhibitor-mediated inhibition of signaling, transformation, and membrane ruffling. *Cancer Res.* 2003; 63:7959–7967. [PubMed: 14633727]
22. Kissil JL, et al. Requirement for Rac1 in a K-ras induced lung cancer in the mouse. *Cancer Res.* 2007; 67:8089–8094. [PubMed: 17804720]
23. Lobell RB, et al. Evaluation of farnesyl:protein transferase and geranylgeranyl:protein transferase inhibitor combinations in preclinical models. *Cancer Res.* 2001; 61:8758–8768. [PubMed: 11751396]
24. O'Dwyer PJ, Gallagher M, Nguyen B, Waddell MJ, Chiorean EG. Phase I accelerated dose-escalating safety and pharmacokinetic (PK) study of GGTI-2418, a novel geranylgeranyltransferase I inhibitor in patients with refractory solid tumors. *Ann Oncol.* 2010; 21:ii42.
25. Raponi M, et al. Identification of molecular predictors of response in a study of tipifarnib treatment in relapsed and refractory acute myelogenous leukemia. *Clin Cancer Res.* 2007; 13:2254–2260. [PubMed: 17404110]
26. Raponi M, et al. A 2-gene classifier for predicting response to the farnesyltransferase inhibitor tipifarnib in acute myeloid leukemia. *Blood.* 2008; 111:2589–2596. These two studies have advanced approaches to correctly predict clinical outcome following FTI therapy. The authors have identified a signature two-gene expression ratio (*RASGRPS1/APTX*) as a predictor for the response to tipifarnib in patients with AML. [PubMed: 18160667]
27. Yang W, Urano J, Tamanoi F. Protein farnesylation is critical for maintaining normal cell morphology and canavanine resistance in *Schizosaccharomyces pombe*. *J Biol Chem.* 2000; 275:429–438. [PubMed: 10617635]
28. Cox AD, Hisaka MM, Buss JE, Der CJ. Specific isoprenoid modification is required for function of normal, but not oncogenic, Ras protein. *Mol Cell Biol.* 1992; 12:2606–2615. [PubMed: 1375323]
29. Perez-Sala D. Protein isoprenylation in biology and disease: general overview and perspectives from studies with genetically engineered animals. *Front Biosci.* 2007; 12:4456–4472. [PubMed: 17485388]
30. Sebti SM. Protein farnesylation: implications for normal physiology, malignant transformation, and cancer therapy. *Cancer Cell.* 2005; 7:297–300. [PubMed: 15837619]
31. Mijimolle N, et al. Protein farnesyltransferase in embryogenesis, adult homeostasis, and tumor development. *Cancer Cell.* 2005; 7:313–324. [PubMed: 15837621]
32. Ohya Y, et al. Yeast CAL1 is a structural and functional homologue to the DPR1 (RAM) gene involved in ras processing. *J Biol Chem.* 1991; 266:12356–12360. [PubMed: 2061313]
33. Therrien M, et al. KSR, a novel protein kinase required for RAS signal transduction. *Cell.* 1995; 83:879–888. [PubMed: 8521512]
34. Sjogren AK, et al. GGTase-I deficiency reduces tumor formation and improves survival in mice with K-RAS-induced lung cancer. *J Clin Invest.* 2007; 117:1294–1304. This article shows that targeted deletion of *Ggt1* in the lung reduces *Kras*-driven tumour formation and increases the lifespan of mice with *Kras*-induced lung cancer. [PubMed: 17476360]
35. Reid TS, Terry KL, Casey PJ, Beese LS. Crystallographic analysis of CaaX prenyltransferases complexed with substrates defines rules of protein substrate selectivity. *J Mol Biol.* 2004; 343:417–433. [PubMed: 15451670]
36. Yang SH, et al. Caution! Analyze transcripts from conditional knockout alleles. *Transgenic Res.* 2009; 18:483–489. [PubMed: 19093225]
37. Liu M, et al. Targeting the protein prenyltransferases efficiently reduces tumor development in mice with K-RAS-induced lung cancer. *Proc Natl Acad Sci USA.* 2010; 107:6471–6476. This article demonstrates that concomitant conditional loss of both FT and GGT1 in mice effectively reduces *Kras*-induced lung carcinogenesis, and extends the lifespan of these mice considerably more than FT or GGT1 deficiency alone, suggesting that the simultaneous inhibition of FT and GGT1 may be therapeutically beneficial in cancer patients. [PubMed: 20308544]
38. Sjogren AK, et al. Inactivating GGTase-I reduces disease phenotypes in a mouse model of K-RAS-induced myeloproliferative disease. *Leukemia.* 2011; 25:186–189. [PubMed: 20975663]



39. Wang T, et al. The p21(RAS) farnesyltransferase  $\alpha$  subunit in TGF- $\beta$  and activin signaling. *Science*. 1996; 271:1120–1122. [PubMed: 8599089]
40. Kumar A, Beresini MH, Dhawan P, Mehta KD.  $\alpha$ -subunit of farnesyltransferase is phosphorylated *in vivo*: effect of protein phosphatase-1 on enzymatic activity. *Biochem Biophys Res Commun*. 1996; 222:445–452. [PubMed: 8670225]
41. Kumar A, Mehta K. D p21ras farnesyltransferase  $\alpha$ - and  $\beta$  ubunits are phosphorylated in PC-12 cells: TGF- $\beta$  signaling pathway independent phosphorylation. *Neurosci Lett*. 1997; 231:143–146. [PubMed: 9300642]
42. Goalstone M, Carel K, Leitner JW, Draznin B. Insulin stimulates the phosphorylation and activity of farnesyltransferase via the Ras-mitogen-activated protein kinase pathway. *Endocrinology*. 1997; 138:5119–5124. [PubMed: 9389491]
43. Kim KW, et al. Inactivation of farnesyltransferase and geranylgeranyltransferase I by caspase-3: cleavage of the common  $\alpha$  subunit during apoptosis. *Oncogene*. 2001; 20:358–366. [PubMed: 11313965]
44. Singh J, Hamid R, Reddy BS. Dietary fish oil inhibits the expression of farnesyl protein transferase and colon tumor development in rodents. *Carcinogenesis*. 1998; 19:985–989. [PubMed: 9667735]
45. Caruso MG, et al. Increased farnesyltransferase activity in human colorectal cancer: relationship with clinicopathological features and K-ras mutation. *Scand J Gastroenterol*. 2003; 38:80–85. [PubMed: 12608469]
46. Lantry LE, et al. Chemopreventive efficacy of promising farnesyltransferase inhibitors. *Exp Lung Res*. 2000; 26:773–790. [PubMed: 11195470]
47. Zhang Z, et al. Farnesyltransferase inhibitors are potent lung cancer chemopreventive agents in A/J. mice with a dominant-negative p53 and/or heterozygous deletion of Ink4a/Arf. *Oncogene*. 2003; 22:6257–6265. [PubMed: 13679864]
48. Lerner EC, et al. Ras CAAX peptidomimetic FTI-277 selectively blocks oncogenic Ras signaling by inducing cytoplasmic accumulation of inactive Ras-Raf complexes. *J Biol Chem*. 1995; 270:26802–26806. [PubMed: 7592920]
49. Jiang K, et al. The phosphoinositide 3-OH kinase/AKT2 pathway as a critical target for farnesyltransferase inhibitor-induced apoptosis. *Mol Cell Biol*. 2000; 20:139–148. [PubMed: 10594016]
50. Sun SY, Zhou Z, Wang R, Fu H, Khuri FR. The farnesyltransferase inhibitor Lonafarnib induces growth arrest or apoptosis of human lung cancer cells without downregulation of Akt. *Cancer Biol Ther*. 2004; 3:1092–1098. discussion 1099–1101. [PubMed: 15467440]
51. Sun J, Qian Y, Hamilton AD, Sebti SM. Ras CAAX peptidomimetic FTI 276 selectively blocks tumor growth in nude mice of a human lung carcinoma with K-Ras mutation and p53 deletion. *Cancer Res*. 1995; 55:4243–4247. [PubMed: 7671229]
52. Manges R, et al. Antitumor effect of a farnesyl protein transferase inhibitor in mammary and lymphoid tumors overexpressing N-ras in transgenic mice. *Cancer Res*. 1998; 58:1253–1259. [PubMed: 9515813]
53. Omer CA, et al. Mouse mammary tumor virus-Ki-*ras*B transgenic mice develop mammary carcinomas that can be growth-inhibited by a farnesyl:protein transferase inhibitor. *Cancer Res*. 2000; 60:2680–2688. [PubMed: 10825141]
54. Crespo NC, Ohkanda J, Yen TJ, Hamilton AD, Sebti SM. The farnesyltransferase inhibitor, FTI-2153, blocks bipolar spindle formation and chromosome alignment and causes prometaphase accumulation during mitosis of human lung cancer cells. *J Biol Chem*. 2001; 276:16161–16167. [PubMed: 11154688]
55. Crespo NC, et al. The farnesyltransferase inhibitor, FTI-2153, inhibits bipolar spindle formation during mitosis independently of transformation and Ras and p53 mutation status. *Cell Death Differ*. 2002; 9:702–709. [PubMed: 12058275]
56. Ashar HR, et al. Farnesyl transferase inhibitors block the farnesylation of CENP-E and CENP-F and alter the association of CENP-E with the microtubules. *J Biol Chem*. 2000; 275:30451–30457. [PubMed: 10852915]
57. Hussein D, Taylor SS. Farnesylation of Cenp-F is required for G2/M progression and degradation after mitosis. *J Cell Sci*. 2002; 115:3403–3414. [PubMed: 12154071]

58. Wang J, Kirby CE, Herbst R. The tyrosine phosphatase PRL-1 localizes to the endoplasmic reticulum and the mitotic spindle and is required for normal mitosis. *J Biol Chem.* 2002; 277:46659–46668. [PubMed: 12235145]
59. Sepp-Lorenzino L, Rosen N. A farnesyl-protein transferase inhibitor induces p21 expression and G1 block in p53 wild type tumor cells. *J Biol Chem.* 1998; 273:20243–20251. [PubMed: 9685373]
60. Reuveni H, Klein S, Levitzki A. The inhibition of Ras farnesylation leads to an increase in p27Kip1 and G1 cell cycle arrest. *Eur J Biochem.* 2003; 270:2759–2772. [PubMed: 12823546]
61. Kohl NE, et al. Inhibition of farnesyltransferase induces regression of mammary and salivary carcinomas in ras transgenic mice. *Nature Med.* 1995; 1:792–797. Using transgenic mice expressing mutant HRAS in the mammary glands, this is the first demonstration that FTIs cause persistent tumour regression *in vivo*. [PubMed: 7585182]
62. Barrington RE, et al. A farnesyltransferase inhibitor induces tumor regression in transgenic mice harboring multiple oncogenic mutations by mediating alterations in both cell cycle control and apoptosis. *Mol Cell Biol.* 1998; 18:85–92. [PubMed: 9418856]
63. Lebowitz PF, Sakamuro D, Prendergast GC. Farnesyl transferase inhibitors induce apoptosis of Ras-transformed cells denied substratum attachment. *Cancer Res.* 1997; 57:708–713. [PubMed: 9044849]
64. Suzuki N, Urano J, Tamanoi F. Farnesyltransferase inhibitors induce cytochrome *c* release and caspase 3 activation preferentially in transformed cells. *Proc Natl Acad Sci USA.* 1998; 95:15356–15361. [PubMed: 9860973]
65. Oh SH, Jin Q, Kim ES, Khuri FR, Lee HY. Insulin-like growth factor-I receptor signaling pathway induces resistance to the apoptotic activities of SCH66336 (lonafarnib) through Akt/mammalian target of rapamycin-mediated increases in survivin expression. *Clin Cancer Res.* 2008; 14:1581–1589. [PubMed: 18316583]
66. Zhang B, Prendergast GC, Fenton RG. Farnesyltransferase inhibitors reverse Ras-mediated inhibition of Fas gene expression. *Cancer Res.* 2002; 62:450–458. [PubMed: 11809695]
67. Takada Y, Khuri FR, Aggarwal BB. Protein farnesyltransferase inhibitor (SCH 66336) abolishes NF- $\kappa$ B activation induced by various carcinogens and inflammatory stimuli leading to suppression of NF- $\kappa$ B-regulated gene expression and up-regulation of apoptosis. *J Biol Chem.* 2004; 279:26287–26299. [PubMed: 15090542]
68. Lackner MR, et al. Chemical genetics identifies Rab geranylgeranyl transferase as an apoptotic target of farnesyl transferase inhibitors. *Cancer Cell.* 2005; 7:325–336. [PubMed: 15837622]
69. Han JY, et al. Hypoxia-inducible factor 1 $\alpha$  and antiangiogenic activity of farnesyltransferase inhibitor SCH66336 in human aerodigestive tract cancer. *J Natl Cancer Inst.* 2005; 97:1272–1286. [PubMed: 16145048]
70. Cohen-Jonathan E, et al. The farnesyltransferase inhibitor L744, 832 reduces hypoxia in tumors expressing activated H-ras. *Cancer Res.* 2001; 61:2289–2293. [PubMed: 11280800]
71. Delmas C, et al. The farnesyltransferase inhibitor R115777 reduces hypoxia and matrix metalloproteinase 2 expression in human glioma xenograft. *Clin Cancer Res.* 2003; 9:6062–6068. [PubMed: 14676133]
72. Kim CK, et al. The farnesyltransferase inhibitor LB42708 suppresses vascular endothelial growth factor-induced angiogenesis by inhibiting ras-dependent mitogen-activated protein kinase and phosphatidylinositol 3-kinase/Akt signal pathways. *Mol Pharmacol.* 2010; 78:142–150. [PubMed: 20406854]
73. Bernhard EJ, et al. The farnesyltransferase inhibitor FTI-277 radiosensitizes H-ras-transformed rat embryo fibroblasts. *Cancer Res.* 1996; 56:1727–1730. [PubMed: 8620483]
74. Moasser MM, et al. Farnesyl transferase inhibitors cause enhanced mitotic sensitivity to taxol and epothilones. *Proc Natl Acad Sci USA.* 1998; 95:1369–1374. [PubMed: 9465021]
75. Basso AD, et al. The farnesyl transferase inhibitor (FTI) SCH66336 (lonafarnib) inhibits Rheb farnesylation and mTOR signaling. Role in FTI enhancement of taxane and tamoxifen anti-tumor activity. *J Biol Chem.* 2005; 280:31101–31108. [PubMed: 16006564]
76. Adjei AA, Davis JN, Bruzek LM, Erlichman C, Kaufmann SH. Synergy of the protein farnesyltransferase inhibitor SCH66336 and cisplatin in human cancer cell lines. *Clin Cancer Res.* 2001; 7:1438–1445. [PubMed: 11350915]

77. Zheng H, et al. Ras homologue enriched in brain is a critical target of farnesyltransferase inhibitors in non-small cell lung cancer cells. *Cancer Lett.* 2010; 297:117–125. In this paper, the response to FTIs was correlated to the expression levels of RHEB in human lung tumour tissue and cell lines. [PubMed: 20554106]
78. Russo P, Malacarne D, Falugi C, Trombino S, O'Connor PM. RPR-115135, a farnesyltransferase inhibitor, increases 5-FU- cytotoxicity in ten human colon cancer cell lines: role of p53. *Int J Cancer.* 2002; 100:266–275. [PubMed: 12115540]
79. Brassard DL, et al. Inhibitors of farnesyl protein transferase and MEK1, 2 induce apoptosis in fibroblasts transformed with farnesylated but not geranylgeranylated H-Ras. *Exp Cell Res.* 2002; 273:138–146. [PubMed: 11822869]
80. Edamatsu H, Gau CL, Nemoto T, Guo L, Tamanoi F. Cdk inhibitors, roscovitine and olomoucine, synergize with farnesyltransferase inhibitor (FTI) to induce efficient apoptosis of human cancer cell lines. *Oncogene.* 2000; 19:3059–3068. [PubMed: 10871858]
81. Hoover RR, Mahon FX, Melo JV, Daley GQ. Overcoming STI571 resistance with the farnesyl transferase inhibitor SCH66336. *Blood.* 2002; 100:1068–1071. [PubMed: 12130526]
82. Liu M, et al. Antitumor activity of SCH 66336, an orally bioavailable tricyclic inhibitor of farnesyl protein transferase, in human tumor xenograft models and wap-ras transgenic mice. *Cancer Res.* 1998; 58:4947–4956. [PubMed: 9810004]
83. Shi B, et al. The farnesyl protein transferase inhibitor SCH66336 synergizes with taxanes *in vitro* and enhances their antitumor activity *in vivo*. *Cancer Chemother Pharmacol.* 2000; 46:387–393. [PubMed: 11127943]
84. Sun J, et al. Antitumor efficacy of a novel class of non-thiol-containing peptidomimetic inhibitors of farnesyltransferase and geranylgeranyltransferase I: combination therapy with the cytotoxic agents cisplatin, Taxol, and gemcitabine. *Cancer Res.* 1999; 59:4919–4926. [PubMed: 10519405]
85. Berndt N, et al. The Akt activation inhibitor TCN-P inhibits Akt phosphorylation by binding to the PH domain of Akt and blocking its recruitment to the plasma membrane. *Cell Death Differ.* 2010; 17:1795–1804. [PubMed: 20489726]
86. Balasis ME, et al. Combination of farnesyltransferase and Akt inhibitors is synergistic in breast cancer cells and causes significant tumor regression in ErbB2 transgenic mice. *Clin Cancer Res.* 2011; 17:2852–2862. [PubMed: 21536547]
87. Marcus AI, et al. The synergistic combination of the farnesyl transferase inhibitor lonafarnib and paclitaxel enhances tubulin acetylation and requires a functional tubulin deacetylase. *Cancer Res.* 2005; 65:3883–3893. [PubMed: 15867388]
88. Marcus AI, et al. Farnesyltransferase inhibitors reverse taxane resistance. *Cancer Res.* 2006; 66:8838–8846. [PubMed: 16951201]
89. Zhou J, et al. The protein farnesyltransferase regulates HDAC6 activity in a microtubule-dependent manner. *J Biol Chem.* 2009; 284:9648–9655. [PubMed: 19228685]
90. Vogt A, Sun J, Qian Y, Hamilton AD, Sefti SM. The geranylgeranyltransferase-I inhibitor GGTI-298 arrests human tumor cells in G0/G1 and induces p21(WAF1/CIP1/SDI1) in a p53-independent manner. *J Biol Chem.* 1997; 272:27224–27229. [PubMed: 9341167]
91. Sun J, et al. The geranylgeranyltransferase I inhibitor GGTI-298 induces hypophosphorylation of retinoblastoma and partner switching of cyclin-dependent kinase inhibitors. A potential mechanism for GGTI-298 antitumor activity. *J Biol Chem.* 1999; 274:6930–6934. [PubMed: 10066746]
92. Kazi A, et al. Blockade of protein geranylgeranylation inhibits Cdk2-dependent p27Kip1 phosphorylation on Thr187 and accumulates p27Kip1 in the nucleus: implications for breast cancer therapy. *Mol Cell Biol.* 2009; 29:2254–2263. This paper demonstrates that the antitumour activity of GGTI-2417 and GGTI-2418 depends on stabilizing p27 via blocking its phosphorylation at Thr187. *In vivo*, GGTI-2418 prevents human breast tumour growth in nude mice and causes breast tumour regression in MMTV-*ErbB2* transgenic mice. [PubMed: 19204084]
93. Watanabe M, et al. Inhibitors of protein geranylgeranyltransferase I and Rab geranylgeranyltransferase identified from a library of allenoate-derived compounds. *J Biol Chem.* 2008; 283:9571–9579. [PubMed: 18230616]

94. Lu J, et al. *In vivo* antitumor effect of a novel inhibitor of protein geranylgeranyltransferase-I. *Mol Cancer Ther.* 2009; 8:1218–1226. [PubMed: 19417142]
95. Dan HC, et al. Phosphatidylinositol-3-OH kinase/AKT and survivin pathways as critical targets for geranylgeranyltransferase I inhibitor-induced apoptosis. *Oncogene.* 2004; 23:706–715. [PubMed: 14737105]
96. Chen S, et al. Dissecting the roles of DR4, DR5 and c-FLIP in the regulation of geranylgeranyltransferase I inhibition-mediated augmentation of TRAIL-induced apoptosis. *Mol Cancer.* 2010; 9:23. [PubMed: 20113484]
97. McGuire TF, Qian Y, Vogt A, Hamilton AD, Sebti SM. Platelet-derived growth factor receptor tyrosine phosphorylation requires protein geranylgeranylation but not farnesylation. *J Biol Chem.* 1996; 271:27402–27407. [PubMed: 8910319]
98. Falsetti SC, et al. Geranylgeranyltransferase I inhibitors target RalB to inhibit anchorage-dependent growth and induce apoptosis and RalA to inhibit anchorage-independent growth. *Mol Cell Biol.* 2007; 27:8003–8014. [PubMed: 17875936]
99. Peterson YK, Kelly P, Weinbaum CA, Casey PJ. A novel protein geranylgeranyltransferase-I inhibitor with high potency, selectivity, and cellular activity. *J Biol Chem.* 2006; 281:12445–12450. [PubMed: 16517596]
100. Peterson YK, Wang XS, Casey PJ, Tropsha A. Discovery of geranylgeranyltransferase-I inhibitors with novel scaffolds by the means of quantitative structure-activity relationship modeling, virtual screening, and experimental validation. *J Med Chem.* 2009; 52:4210–4220. [PubMed: 19537691]
101. Zujewski J, et al. Phase I and pharmacokinetic study of farnesyl protein transferase inhibitor R115777 in advanced cancer. *J Clin Oncol.* 2000; 18:927–941. This is, to our knowledge, the first published report of a clinical trial with an FTI (tipifarnib). [PubMed: 10673536]
102. Lobell RB, et al. Preclinical and clinical pharmacodynamic assessment of L-778, 123, a dual inhibitor of farnesyl:protein transferase and geranylgeranyl:protein transferase type-I. *Mol Cancer Ther.* 2002; 1:747–758. [PubMed: 12479371]
103. Kauh J, et al. Farnesyl transferase expression determines clinical response to the docetaxel-lonafarnib combination in patients with advanced malignancies. *Cancer.* 2011; 117:4049–4059. [PubMed: 21365629]
104. Sepp-Lorenzino L, et al. A peptidomimetic inhibitor of farnesyl:protein transferase blocks the anchorage-dependent and -independent growth of human tumor cell lines. *Cancer Res.* 1995; 55:5302–5309. [PubMed: 7585592]
105. End DW, et al. Characterization of the antitumor effects of the selective farnesyl protein transferase inhibitor R115777 *in vivo* and *in vitro*. *Cancer Res.* 2001; 61:131–137. [PubMed: 11196150]
106. Kurzrock R, et al. Farnesyltransferase inhibitor R115777 in myelodysplastic syndrome: clinical and biologic activities in the phase 1 setting. *Blood.* 2003; 102:4527–4534. [PubMed: 12947010]
107. Kohl NE, et al. Protein farnesyltransferase inhibitors block the growth of ras-dependent tumors in nude mice. *Proc Natl Acad Sci USA.* 1994; 91:9141–9145. [PubMed: 8090782]
108. Tee AR, Manning BD, Roux PP, Cantley IC, Blenis J. Tuberous sclerosis complex gene products, tuberin and hamartin, control mTOR signaling by acting as a GTPase-activating protein complex toward Rheb. *Curr Biol.* 2003; 13:1259–1268. [PubMed: 12906785]
109. Garami A, et al. Insulin activation of Rheb, a mediator of mTOR/S6K/4E-BP signaling, is inhibited by TSC1 and 2. *Mol Cell.* 2003; 11:1457–1466. [PubMed: 12820960]
110. Zhang Y, et al. Rheb is a direct target of the tuberous sclerosis tumor suppressor proteins. *Nature Cell Biol.* 2003; 5:578–581. [PubMed: 12771962]
111. Inoki K, Li Y, Zhu T, Wu J, Guan KL. TSC2 is phosphorylated and inhibited by Akt and suppresses mTOR signalling. *Nature Cell Biol.* 2002; 4:648–657. [PubMed: 12172553]
112. Potter CJ, Pedraza LG, Xu T. Akt regulates growth by directly phosphorylating Tsc2. *Nature Cell Biol.* 2002; 4:658–665. [PubMed: 12172554]
113. Manning BD, Tee AR, Logsdon MN, Blenis J, Cantley LC. Identification of the tuberous sclerosis complex-2 tumor suppressor gene product tuberin as a target of the phosphoinositide 3-kinase/akt pathway. *Mol Cell.* 2002; 10:151–162. [PubMed: 12150915]

114. Castro AF, Rebhun JF, Clark GJ, Quilliam LA. Rheb binds tuberous sclerosis complex 2 (TSC2) and promotes S6 kinase activation in a rapamycin- and farnesylation-dependent manner. *J Biol Chem.* 2003; 278:32493–32496. [PubMed: 12842888]
115. Tabancay AP, et al. Identification of dominant negative mutants of Rheb GTPase and their use to implicate the involvement of human Rheb in the activation of p70S76K. *J Biol Chem.* 2003; 278:39921–39930. [PubMed: 12869548]
116. Patel PH, et al. *Drosophila* Rheb GTPase is required for cell cycle progression and cell growth. *J Cell Sci.* 2003; 116:3601–3610. This paper shows that RHEB is required for cell growth (and cell cycle progression). [PubMed: 12893813]
117. Long X, Lin Y, Ortiz-Vega S, Yonezawa K, Avruch J. Rheb binds and regulates the mTOR kinase. *Curr Biol.* 2005; 15:702–713. [PubMed: 15854902]
118. Bai X, et al. Rheb activates mTOR by antagonizing its endogenous inhibitor, FKBP38. *Science.* 2007; 318:977–980. [PubMed: 17991864]
119. Gromov PS, Madsen P, Tomerup N, Celis JE. A novel approach for expression cloning of small GTPases: identification, tissue distribution and chromosome mapping of the human homolog of rheb. *FEBS Lett.* 1995; 377:221–226. [PubMed: 8543055]
120. Mavrakis KJ, et al. Tumorigenic activity and therapeutic inhibition of Rheb GTPase. *Genes Dev.* 2008; 22:2178–2188. In this paper, RHEB was identified as a factor capable of enhancing lymphomagenesis in the *Eμ-Myc* transgenic mouse. Importantly, inhibition of RHEB farnesylation by FTI-277 was identified as a major factor contributing to the antitumour effect of the FTI, suggesting that in lymphomas, and perhaps other haematological malignancies, RHEB is an important target for FTIs. [PubMed: 18708578]
121. Ravikumar B, et al. Inhibition of mTOR induces autophagy and reduces toxicity of polyglutamine expansions in fly and mouse models of Huntington disease. *Nature Genet.* 2004; 36:585–595. [PubMed: 15146184]
122. Pan J, et al. Autophagy induced by farnesyltransferase inhibitors in cancer cells. *Cancer Biol Ther.* 2008; 7:1679–1684. [PubMed: 18769123]
123. Du W, Lebowitz PF, Prendergast GC. Cell growth inhibition by farnesyltransferase inhibitors is mediated by gain of geranylgeranylated RhoB. *Mol Cell Biol.* 1999; 19:1831–1840. [PubMed: 10022870]
124. Du W, Prendergast GC. Geranylgeranylated RhoB mediates suppression of human tumor cell growth by farnesyltransferase inhibitors. *Cancer Res.* 1999; 59:5492–5496. [PubMed: 10554025]
125. Mazières J, et al. Geranylgeranylated, but not farnesylated, RhoB suppresses Ras transformation of NIH-3T3 cells. *Exp Cell Res.* 2005; 304:354–364. [PubMed: 15748883]
126. Chen Z, et al. Both farnesylated and geranylgeranylated RhoB inhibit malignant transformation and suppress human tumor growth in nude mice. *J Biol Chem.* 2000; 275:17974–17978. [PubMed: 10770919]
127. Adnane J, Muro-Cacho C, Mathews L, Sebti SM, Munoz-Antonia T. Suppression of rho B expression in invasive carcinoma from head and neck cancer patients. *Clin Cancer Res.* 2002; 8:2225–2232. [PubMed: 12114424]
128. Forget MA, et al. The expression of rho proteins decreases with human brain tumor progression: potential tumor markers. *Clin Exp Metastasis.* 2002; 19:9–15. [PubMed: 11918088]
129. Mazières J, et al. Loss of RhoB expression in human lung cancer progression. *Clin Cancer Res.* 2004; 10:2742–2750. [PubMed: 15102679]
130. Lebowitz PF, Casey PJ, Prendergast GC, Thissen JA. Farnesyltransferase inhibitors alter the prenylation and growth-stimulating function of RhoB. *J Biol Chem.* 1997; 272:15591–15594. [PubMed: 9188444]
131. Armstrong SA, Hannah VC, Goldstein JL, Brown MS. CAAX geranylgeranyl transferase transfers farnesyl as efficiently as geranylgeranyl to RhoB. *J Biol Chem.* 1995; 270:7864–7868. [PubMed: 7713879]
132. Delarue FL, et al. Farnesyltransferase and geranylgeranyltransferase I inhibitors upregulate RhoB expression by HDAC1 dissociation, HAT association and histone acetylation of the RhoB promoter. *Oncogene.* 2007; 26:633–640. [PubMed: 16909123]

133. Liu A, Du W, Liu JP, Jessell TM, Prendergast GC. RhoB alteration is necessary for apoptotic and antineoplastic responses to farnesyltransferase inhibitors. *Mol Cell Biol.* 2000; 20:6105–6113. [PubMed: 10913192]
134. Xu F, et al. The human ARHI tumor suppressor gene inhibits lactation and growth in transgenic mice. *Cancer Res.* 2000; 60:4913–4920. [PubMed: 10987306]
135. Finlin BS, et al. RERG is a novel ras-related, estrogen-regulated and growth-inhibitory gene in breast cancer. *J Biol Chem.* 2001; 276:42259–42267. [PubMed: 11533059]
136. Hamaguchi M, et al. DBC2, a candidate for a tumor suppressor gene involved in breast cancer. *Proc Natl Acad Sci USA.* 2002; 99:13647–13652. [PubMed: 12370419]
137. Ellis CA, et al. Rig is a novel Ras-related protein and potential neural tumor suppressor. *Proc Natl Acad Sci USA.* 2002; 99:9876–9881. [PubMed: 12107278]
138. Elam C, et al. RRP22 is a farnesylated, nucleolar, ras-related protein with tumor suppressor potential. *Cancer Res.* 2005; 65:3117–3125. [PubMed: 15833841]
139. Boyartchuk VL, Ashby MN, Rine J. Modulation of Ras and  $\alpha$ -factor function by carboxyl-terminal proteolysis. *Science.* 1997; 275:1796–1800. [PubMed: 9065405]
140. Bergo MO, et al. Inactivation of Icm1 inhibits transformation by oncogenic K-Ras and B-Raf. *J Clin Invest.* 2004; 113:539–550. [PubMed: 14966563]
141. Linder ME, Deschenes RJ. Palmitoylation: policing protein stability and traffic. *Nature Rev Mol Cell Biol.* 2007; 8:74–84. [PubMed: 17183362]
142. Bergo MO, et al. Absence of the CAAX endoprotease Rce1: effects on cell growth and transformation. *Mol Cell Biol.* 2002; 22:171–181. [PubMed: 11739732]
143. Wang M, et al. Inhibition of isoprenylcysteine carboxylmethyltransferase induces autophagic-dependent apoptosis and impairs tumor growth. *Oncogene.* 2010; 29:4959–4970. [PubMed: 20622895]
144. Forget MA, Desrosiers RR, Gingras D, Beliveau R. Phosphorylation states of Cdc42 and RhoA regulate their interactions with Rho GDP dissociation inhibitor and their extraction from biological membranes. *Biochem J.* 2002; 361:243–254. [PubMed: 11772396]
145. Bivona TG, et al. PKC regulates a farnesyl-electrostatic switch on K-Ras that promotes its association with Bcl-XL on mitochondria and induces apoptosis. *Mol Cell.* 2006; 21:481–493. This article highlights a long neglected aspect of KRAS regulation, namely phosphorylation of KRAS at Ser181 and its functional consequences: PKC-mediated phosphorylation at this site, which is located within the polybasic region of the KRAS C terminus, converts KRAS from an oncogenic protein into a pro-apoptotic protein. [PubMed: 16483930]
146. Rundell CJ, Repellin CE, Yarwood SJ. Protease inhibitors prevent the protein kinase A-dependent loss of Rap1 GTPase from the particulate fraction of COS1 cells. *Biochem Biophys Res Commun.* 2004; 315:1077–1081. [PubMed: 14985123]
147. Lang P, et al. Protein kinase A phosphorylation of RhoA mediates the morphological and functional effects of cyclic AMP in cytotoxic lymphocytes. *EMBO J.* 1996; 15:510–519. [PubMed: 8599934]
148. Fitzgerald ML, Reed GL. Rab6 is phosphorylated in thrombin-activated platelets by a protein kinase C-dependent mechanism: effects on GTP/GDP binding and cellular distribution. *Biochem J.* 1999; 342:353–360. [PubMed: 10455022]
149. Riento K, et al. RhoE function is regulated by ROCK I-mediated phosphorylation. *EMBO J.* 2005; 24:1170–1180. [PubMed: 15775972]
150. Sablina AA, et al. The tumor suppressor PP2A A $\beta$  regulates the RalA GTPase. *Cell.* 2007; 129:969–982. [PubMed: 17540176]
151. Lim KH, et al. Aurora-A phosphorylates, activates, and relocalizes the small GTPase RalA. *Mol Cell Biol.* 2010; 30:508–523. References 150 and 151 demonstrate that the transforming activity of RALA not only depends on prenylation, but also on phosphorylation at Ser194, which is controlled by aurora kinase A and PP2A. These findings may pave the way for new therapeutic opportunities, such as combining GGTIs with aurora kinase inhibitors. [PubMed: 19901077]
152. Kwon T, Kwon DY, Chun J, Kim JH, Kang SS. Akt protein kinase inhibits Rac1-GTP binding through phosphorylation at serine 71 of Rac1. *J Biol Chem.* 2000; 275:423–428. [PubMed: 10617634]

153. Tillement V, et al. Phosphorylation of RhoB by CK1 impedes actin stress fiber organization and epidermal growth factor receptor stabilization. *Exp Cell Res.* 2008; 314:2811–2821. [PubMed: 18590726]
154. Zheng M, et al. Inactivation of Rheb by PRAK-mediated phosphorylation is essential for energy-depletion-induced suppression of mTORC1. *Nature Cell Biol.* 2011; 13:263–272. [PubMed: 21336308]
155. Sarthy AV, et al. Survivin depletion preferentially reduces the survival of activated K-Ras-transformed cells. *Mol Cancer Ther.* 2007; 6:269–276. [PubMed: 17237286]
156. Barbie DA, et al. Systematic RNA interference reveals that oncogenic KRAS-driven cancers require TBK1. *Nature.* 2009; 462:108–112. [PubMed: 19847166]
157. Scholl C, et al. Synthetic lethal interaction between oncogenic KRAS dependency and STK33 suppression in human cancer cells. *Cell.* 2009; 137:821–834. [PubMed: 19490892]
158. Luo J, et al. A genome-wide RNAi screen identifies multiple synthetic lethal interactions with the Ras oncogene. *Cell.* 2009; 137:835–848. [PubMed: 19490893]
159. Singh A, et al. A gene expression signature associated with “K-Ras addiction” reveals regulators of EMT and tumor cell survival. *Cancer Cell.* 2009; 15:489–500. [PubMed: 19477428]
160. Puyol M, et al. A synthetic lethal interaction between K-Ras oncogenes and Cdk4 unveils a therapeutic strategy for non-small cell lung carcinoma. *Cancer Cell.* 2010; 18:63–73. References 155–160 are particularly important as they identify novel promising targets for cancer patients whose tumours depend on KRAS for survival. Importantly, the four protein kinases identified are not essential for the survival of normal cells, but their loss of function in combination with activated KRAS is synthetically lethal. Reference 159 also emphasizes the point that not all KRAS-mutant cell lines are addicted to KRAS, suggesting that in a subset of tumours, KRAS may not be a suitable target. [PubMed: 20609353]
161. Williams JP, et al. The retinoblastoma protein is required for Ras-induced oncogenic transformation. *Mol Cell Biol.* 2006; 26:1170–1182. This paper provides evidence that RAS-dependent transformation requires the presence of functional RB, a major tumour suppressor. Although this study uses murine fibroblasts, its findings may explain the fact that activating mutations of RAS and inactivating mutations of RB rarely occur together in human cancers. [PubMed: 16449633]
162. Filmus J, et al. Induction of cyclin D1 overexpression by activated ras. *Oncogene.* 1994; 9:3627–3633. [PubMed: 7970723]
163. Weinberg RA. The retinoblastoma protein and cell cycle control. *Cell.* 1995; 81:323–330. [PubMed: 7736585]
164. Kaye FJ. RB and cyclin dependent kinase pathways: defining a distinction between RB and p16 loss in lung cancer. *Oncogene.* 2002; 21:6908–6914. [PubMed: 12362273]
165. Maurer-Stroh S, et al. Towards complete sets of farnesylated and geranylgeranylated proteins. *PLoS Comp Biol.* 2007; 3:e66. More than 100 proteins have been experimentally confirmed to undergo prenylation, but the exact size of the prenylome is unknown. This paper describes methods to better predict whether a potentially prenylatable protein is a substrate for FT, GGT1 or GGT2. These take into account the requirement for specific residues within the CaaX box, evolutionary conservation of the prenylation motif across phyla and physicochemical constraints extending up to 11 residues upstream of the prenylatable Cys.
166. Lane KT, Beese LS. Thematic review series: lipid posttranslational modifications. Structural biology of protein farnesyltransferase and geranylgeranyltransferase type I. *J Lipid Res.* 2006; 47:681–699. [PubMed: 16477080]
167. Berndt N, Sebti SM. Measuring protein farnesylation and geranylgeranylation and using prenyltransferase inhibitors as chemical probes and anticancer agents. *Nature Protoc.* (in the press).
168. Kho Y, et al. A tagging-via-substrate technology for detection and proteomics of farnesylated proteins. *Proc Natl Acad Sci USA.* 2004; 101:12479–12484. [PubMed: 15308774]
169. Troutman JM, Roberts MJ, Andres DA, Spielmann HP. Tools to analyze protein farnesylation in cells. *Bioconjug Chem.* 2005; 16:1209–1217. [PubMed: 16173800]

170. Nguyen UT, et al. Analysis of the eukaryotic prenylome by isoprenoid affinity tagging. *Nature Chem Biol.* 2009; 5:227–235. [PubMed: 19219049]
171. Onono FO, et al. A tagging-via-substrate approach to detect the farnesylated proteome using two-dimensional electrophoresis coupled with Western blotting. *Mol Cell Proteomics.* 2010; 9:742–751. [PubMed: 20103566]
172. Chan LN, et al. A novel approach to tag and identify geranylgeranylated proteins. *Electrophoresis.* 2009; 30:3598–3606. [PubMed: 19784953]
173. Degraw AJ, et al. Evaluation of alkyne-modified isoprenoids as chemical reporters of protein prenylation. *Chem Biol Drug Des.* 2010; 76:460–471. References 168–173 considerably advance our abilities to describe the effects of PTIs on the entire prenylome rather than just individual proteins. This is needed to identify prenylated proteins the inhibition of which contributes to the antitumour effects of PTIs. [PubMed: 21040496]
174. Willumsen BM, Christensen A, Hubbert NL, Papageorge AG, Lowy DR. The p21 ras C-terminus is required for transformation and membrane association. *Nature.* 1984; 310:583–586. [PubMed: 6087162]
175. Willumsen BM, Norris K, Papageorge AG, Hubbert NL, Lowy DR. Harvey murine sarcoma virus p21 ras protein: biological and biochemical significance of the cysteine nearest the carboxy terminus. *EMBO J.* 1984; 3:2581–2585. Although when references 174 and 175 were published it was unknown that RAS is farnesylated, these studies are important as they demonstrated that the C terminus of RAS is essential for both its membrane binding and its transforming activity. [PubMed: 6096132]
176. Seabra MC, Reiss Y, Casey PJ, Brown MS, Goldstein JL. Protein farnesyltransferase and geranylgeranyltransferase share a common  $\alpha$  subunit. *Cell.* 1991; 65:429–434. [PubMed: 2018975]
177. Zhang FL, et al. cDNA cloning and expression of rat and human protein geranylgeranyltransferase type-I. *J Biol Chem.* 1994; 269:3175–3180. [PubMed: 8106351]
178. Park HW, Boduluri SR, Moomaw JF, Casey PJ, Beese LS. Crystal structure of protein farnesyltransferase at 2.25 angstrom resolution. *Science.* 1997; 275:1800–1804. [PubMed: 9065406]
179. Huang CC, Casey PJ, Fierke CA. Evidence for a catalytic role of zinc in protein farnesyltransferase. Spectroscopy of  $\text{Co}^{2+}$ -farnesyltransferase indicates metal coordination of the substrate thiolate. *J Biol Chem.* 1997; 272:20–23. [PubMed: 8995218]
180. Zhang FL, Casey PJ. Protein prenylation: molecular mechanisms and functional consequences. *Annu Rev Biochem.* 1996; 65:241–269. [PubMed: 8811180]
181. Carboni JM, et al. Farnesyltransferase inhibitors are inhibitors of Ras but not R-Ras2/TC21, transformation. *Oncogene.* 1995; 10:1905–1913. [PubMed: 7761092]
182. Moores SL, et al. Sequence dependence of protein isoprenylation. *J Biol Chem.* 1991; 266:14603–14610. [PubMed: 1860864]
183. Boutin JA, et al. Chromatographic assay and peptide substrate characterization of partially purified farnesyl- and geranylgeranyltransferases from rat brain cytosol. *Arch Biochem Biophys.* 1998; 354:83–94. [PubMed: 9633601]
184. Eriksson M, et al. Recurrent *de novo* point mutations in lamin A cause Hutchinson-Gilford progeria syndrome. *Nature.* 2003; 423:293–298. [PubMed: 12714972]
185. Young SG, Fong LG, Michaelis S. Prelamin A, Zmpste24, misshapen cell nuclei, and progeria—new evidence suggesting that protein farnesylation could be important for disease pathogenesis. *J Lipid Res.* 2005; 46:2531–2558. [PubMed: 16207929]
186. Mallampalli MP, Huyer G, Bendale P, Gelb MH, Michaelis S. Inhibiting farnesylation reverses the nuclear morphology defect in a HeLa cell model for Hutchinson-Gilford progeria syndrome. *Proc Natl Acad Sci USA.* 2005; 102:14416–14421. [PubMed: 16186497]
187. Toth JI, et al. Blocking protein farnesyltransferase improves nuclear shape in fibroblasts from humans with progeroid syndromes. *Proc Natl Acad Sci USA.* 2005; 102:12873–12878. [PubMed: 16129834]



188. Yang SH, et al. Blocking protein farnesyltransferase improves nuclear blebbing in mouse fibroblasts with a targeted Hutchinson-Gilford progeria syndrome mutation. *Proc Natl Acad Sci USA*. 2005; 102:10291–10296. [PubMed: 16014412]
189. Fong LG, et al. A protein farnesyltransferase inhibitor ameliorates disease in a mouse model of progeria. *Science*. 2006; 311:1621–1623. [PubMed: 16484451]
190. Yang SH, et al. Assessing the efficacy of protein farnesyltransferase inhibitors in mouse models of progeria. *J Lipid Res*. 2010; 51:400–405. [PubMed: 19965595]
191. Work LM, et al. Short-term local delivery of an inhibitor of Ras farnesyltransferase prevents neointima formation *in vivo* after porcine coronary balloon angioplasty. *Circulation*. 2001; 104:1538–1543. [PubMed: 11571249]
192. Finder JD, et al. Inhibition of protein geranylgeranylation causes a superinduction of nitric-oxide synthase-2 by interleukin-1 $\beta$  in vascular smooth muscle cells. *J Biol Chem*. 1997; 272:13484–13488. [PubMed: 9153192]
193. Eastman RT, Buckner FS, Yokoyama K, Gelb MH, Van Voorhis WC. Thematic review series: lipid posttranslational modifications. Fighting parasitic disease by blocking protein farnesylation. *J Lipid Res*. 2006; 47:233–240. [PubMed: 16339110]
194. Carrico D, et al. *In vitro* and *in vivo* antimalarial activity of peptidomimetic protein farnesyltransferase inhibitors with improved membrane permeability. *Bioorg Med Chem*. 2004; 12:6517–6526. [PubMed: 15556768]
195. Nallan L, et al. Protein farnesyltransferase inhibitors exhibit potent antimalarial activity. *J Med Chem*. 2005; 48:3704–3713. [PubMed: 15916422]
196. Yokoyama K, Gillespie JR, Van Voorhis WC, Buckner FS, Gelb MH. Protein geranylgeranyltransferase-I of *Trypanosoma cruzi*. *Mol Biochem Parasitol*. 2008; 157:32–43. [PubMed: 17996962]
197. Bordier BB, et al. *In vivo* antiviral efficacy of prenylation inhibitors against hepatitis delta virus. *J Clin Invest*. 2003; 112:407–414. [PubMed: 12897208]
198. Walters, et al. Inhibition of Rho GTPases with protein prenyltransferase inhibitors prevents leukocyte recruitment to the central nervous system and attenuates clinical signs of disease in an animal model of multiple sclerosis. *J Immunol*. 2002; 168:4087–4094. [PubMed: 11937568]
199. Coxon FP, et al. Protein geranylgeranylation is required for osteoclast formation, function, and survival: inhibition by bisphosphonates and GGTI-298. *J Bone Miner Res*. 2000; 15:1467–1476. [PubMed: 10934645]
200. Kucich U, et al. Requirement for geranylgeranyl transferase I and acyl transferase in the TGF- $\beta$ -stimulated pathway leading to elastin mRNA stabilization. *Biochem Biophys Res Commun*. 1998; 252:111–116. [PubMed: 9813154]
201. Kamiya Y, Sakurai A, Tamura S, Takahashi N. Structure of rhodotorucine A, a novel lipopeptide, inducing mating tube formation in *Rhodospiridium toruloides*. *Biochem Biophys Res Commun*. 1978; 83:1077–1083. [PubMed: 708426]
202. Der CJ, Krontiris TG, Cooper GM. Transforming genes of human bladder and lung carcinoma cell lines are homologous to the ras genes or Harvey and Kirsten sarcoma viruses. *Proc Natl Acad Sci USA*. 1982; 79:3637–3640. [PubMed: 6285355]
203. Parada LF, Tabin CJ, Shih C, Weinberg RA. Human EJ bladder carcinoma oncogene is homologue of Harvey sarcoma virus ras gene. *Nature*. 1982; 297:474–478. [PubMed: 6283357]
204. Mulcahy LS, Smith MR, Stacey DW. Requirement for ras proto-oncogene function during serum-stimulated growth of NIH 3T3 cells. *Nature*. 1985; 313:241–243. [PubMed: 3918269]
205. Powers S, et al. RAM, a gene of yeast required for a functional modification of RAS proteins and for production of mating pheromone  $\alpha$ -factor. *Cell*. 1986; 47:413–422. [PubMed: 3533274]
206. Wolda SL, Glomset JA. Evidence for modification of lamin B by a product of mevalonic acid. *J Biol Chem*. 1988; 263:5997–6000. [PubMed: 3283116]
207. Farnsworth CC, Wolda SL, Gelb MH, Glomset JA. Human lamin B contains a farnesylated cysteine residue. *J Biol Chem*. 1989; 264:20422–20429. [PubMed: 2684976]
208. Casey PJ, Solski PA, Der CJ, Buss J. E p21ras is modified by a farnesyl isoprenoid. *Proc Natl Acad Sci USA*. 1989; 86:8323–8327. [PubMed: 2682646]

209. Hancock JF, Magee AI, Childs JE, Marshall CJ. All ras proteins are polyisoprenylated but only some are palmitoylated. *Cell*. 1989; 57:1167–1177. [PubMed: 2661017]
210. Rilling HC, Breunger E, Epstein WW, Crain PF. Prenylated proteins: the structure of the isoprenoid group. *Science*. 1990; 247:318–320. [PubMed: 2296720]
211. Farnsworth CC, Gelb MH, Glomset JA. Identification of geranylgeranyl-modified proteins in HeLa cells. *Science*. 1990; 247:320–322. [PubMed: 2296721]
212. Yamane HK, et al. Brain G protein  $\gamma$  subunits contain an all-trans-geranylgeranyl cysteine methyl ester at their carboxyl termini. *Proc Natl Acad Sci USA*. 1990; 87:5868–5872. [PubMed: 2116010]
213. Mumby SM, Casey PJ, Gilman AG, Gutowski S, Sternweis PC. G protein  $\gamma$  subunits contain a 20-carbon isoprenoid. *Proc Natl Acad Sci USA*. 1990; 87:5873–5877. [PubMed: 2116011]
214. Reiss Y, Goldstein JL, Seabra MC, Casey PJ, Brown MS. Inhibition of purified p21ras farnesyl:protein transferase by Cys-AAX tetrapeptides. *Cell*. 1990; 62:81–88. [PubMed: 2194674]
215. Kitten GT, Nigg EA. The CaaX motif is required for isoprenylation, carboxyl methylation, and nuclear membrane association of lamin B2. *J Cell Biol*. 1991; 113:13–23. [PubMed: 2007618]
216. Kohl NE, et al. Selective inhibition of ras-dependent transformation by a farnesyltransferase inhibitor. *Science*. 1993; 260:1934–1937. [PubMed: 8316833]
217. Garcia AM, Rowell C, Ackermann K, Kowalczyk JJ, Lewis MD. Peptidomimetic inhibitors of Ras farnesylation and function in whole cells. *J Biol Chem*. 1993; 268:18415–18418. [PubMed: 8360140]
218. Nigam M, Seong CM, Qian Y, Hamilton AD, Sebt SM. Potent inhibition of human tumor p21ras farnesyltransferase by A1A2-lacking p21ras CA1A2X peptidomimetics. *J Biol Chem*. 1993; 268:20695–20698. [PubMed: 8407887]
219. James GL, et al. Benzodiazepine peptidomimetics: potent inhibitors of Ras farnesylation in animal cells. *Science*. 1993; 260:1937–1942. [PubMed: 8316834]
220. Gibbs JB, et al. Selective inhibition of farnesyl-protein transferase blocks ras processing *in vivo*. *J Biol Chem*. 1993; 268:7617–7620. [PubMed: 8463291]
221. Hara M, et al. Identification of Ras farnesyltransferase inhibitors by microbial screening. *Proc Natl Acad Sci USA*. 1993; 90:2281–2285. [PubMed: 8460134]

### At a glance


- Post-translational modifications with the lipids farnesyl or geranylgeranyl (together referred to as prenyl) are catalysed by farnesyltransferase (FT) or geranylgeranyltransferase 1 (GGT1) and are required for the cellular localization, function and cancer-causing activities of some proteins. Among the hundreds of proteins that are estimated to be prenylated most are either exclusively farnesylated (for example, HRAS and RAS homologue enriched in brain (RHEB)) or geranylgeranylated (for example, RHOA, RHOC, RALA and RALB); some are both farnesylated and geranylgeranylated (RHOB), and others are naturally farnesylated but become geranylgeranylated when FT is inhibited (for example, KRAS and NRAS).
- These and other important observations prompted the design and development of inhibitors of FT (FTIs) and GGT1 (GGTIs) as potential anticancer drugs. Several FTIs have been tested clinically but only one GGTI has recently entered clinical trials.
- Further validation of FT and GGT1 as anticancer drug targets was recently provided by genetic mouse models: conditional loss of FT and/or GGT1 hampers mutant KRAS-induced tumorigenesis and extends the lifespan of mice.
- FTI treatment results in the reversal of several hallmarks of cancer, including mitotic arrest at prometaphase, induction of apoptosis, inhibition of anchorage-dependent and anchorage-independent growth, invasion, angiogenesis and tumour growth, as well as induction of tumour regression in animal models. These effects seem to be mediated by interference with aberrant signal transduction pathways such as RAF–MEK–ERK, PI3K–AKT, and other oncogenic and survival pathways.
- GGTI treatment also results in the reversal of the cancer hallmarks mentioned above except that they block cells in the G1 phase of the cell cycle, and this seems to be owing to their ability to induce the accumulation of the cyclin-dependent kinase (CDK) inhibitors p21 and p27 and to inhibit CDKs and induce hypophosphorylation of RB. GGTI treatment also decreases the levels of phospho-AKT and survivin, and this seems to mediate their ability to induce apoptosis.
- Although in preclinical models FTIs are highly effective as antitumour agents, in clinical trials limited efficacy was observed. This is primarily due to poor patient selection. This in turn is due to our lack of understanding of the mechanism of action of FTIs. In the future, a major effort must be dedicated to identifying the prenylated proteins the inhibition of which is responsible for the antitumour effects of FTIs. This will be of great value not only for enhancing our understanding of the mechanism of action of FTIs and GGTIs, but also for selecting patients whose tumours are addicted to specific prenylated proteins and who are more likely to respond to these agents. Recent advances in

techniques to characterize the human prenylome are likely to accelerate achieving these crucial goals in the prenylation field.

**Box 1****Biochemistry of protein prenylation**

Prenylation is a universal lipid post-translational modification (PTM) of cysteine residues near the carboxyl terminus that facilitates membrane association<sup>174,175</sup>. Using farnesyl diphosphate (FPP) or geranylgeranyl diphosphate (GGPP) as the lipid donor, this enzymatically catalysed PTM transfers either a C<sub>15</sub> farnesyl (F) or a C<sub>20</sub> geranylgeranyl (GG) group to the sulphhydryl group of the cysteine residue, thus forming covalent thioether bonds. In eukaryotic cells, prenylation is catalysed by three 'housekeeping' enzymes, farnesyltransferase (FT), geranylgeranyltransferase 1 (GGT1) and GGT2. We focus on FT and GGT1. FT and GGT1 are cytosolic heterodimeric proteins that share a common  $\alpha$ -subunit<sup>176</sup>, but that have homologous but distinct  $\beta$ -subunits<sup>177</sup>. The crystal structure of FT shows a crescent-shaped helical hairpin domain and an  $\alpha$ - $\alpha$  barrel domain<sup>178</sup>. Both FT and GGT1 are metalloenzymes that require zinc for catalysing the covalent binding of the prenyl group carbon to the CaaX cysteine thiol<sup>179</sup>.

Enzyme kinetics and other biochemical studies indicated that FPP first binds to FT, which is followed by the binding of the protein substrate, with prenylation of the substrate occurring much faster than the release of the farnesylated protein product. Proteins modified by FT or GGT1 seem to share a conserved C-terminal CaaX recognition motif (in which C is cysteine, a is an aliphatic amino acid and X is variable). The nature of the C-terminal residue X specifies whether a protein is a substrate for FT or for GGT1: whereas FT prefers X to be methionine, serine, glutamine or cysteine, GGT1 prefers X to be leucine or isoleucine<sup>180</sup>. However, these rules are not absolute: for example, a CaaX protein with a C-terminal phenylalanine can be farnesylated or geranylgeranylated<sup>181</sup>. And although GGT1 clearly prefers X to be leucine<sup>182</sup>, some CaaL motifs can also be farnesylated by FT<sup>183</sup>. Furthermore, at least one protein, RHOB (CaaX box sequence: CKVL), is naturally both farnesylated and geranylgeranylated<sup>35</sup>. Proteins with a C-terminal CaaX box can undergo up to three additional PTMs (see part **a** of the figure). Some proteins such as KRAS-4B (CaaX box sequence: CVIM) and NRAS (CaaX box sequence: CVVM) are naturally only farnesylated, but can be geranylgeranylated and remain fully functional in the presence of an FTI (see part **b** of the figure). To block KRAS function would thus require the inhibition of both FT and GGT1 (REFS 12–15). It is not known how many other farnesylated proteins can be cross-prenylated by GGT1, but the presence of a C-terminal methionine seems to be important for the ability of proteins to undergo cross-prenylation.




**Box 2****The use of FTIs in other diseases**

An unexpected benefit of farnesyltransferase (FT) inhibitors (FTIs) may be their potential to treat diseases other than cancer. Hutchinson–Gilford progeria syndrome (HGPS) is a genetic disease that is associated with premature ageing and death, normally from heart failure, at about 13 years of age. HGPS is linked to a mutation in *LMNA* that prevents prelamin A (a substrate for FT) from proper maturation into lamin A. Normal processing of prelamin A involves, among other steps, the removal of a carboxy-terminal peptide containing farnesylcysteine. Children with HGPS are unable to perform this step, which results in a mutant form of lamin A, termed progerin<sup>184</sup>, which is persistently farnesylated and non-functional<sup>185</sup>. In fibroblasts derived from patients with HGPS and mice, as well as HeLa cells, FTIs can prevent the aberrant nuclear morphology of cells that express progerin<sup>186–188</sup>. In mouse models of HGPS, FTIs greatly improve the phenotype of HGPS with respect to lifespan, body weight and bone integrity<sup>189</sup>. Furthermore, the crucial target for FTI treatment was confirmed to be progerin<sup>190</sup>. These results suggest that FTIs may be beneficial for children with HGPS, and lonafarnib is currently being tested in clinical trials.

A common problem in the treatment of cardiovascular diseases is the hyperproliferation of smooth muscle cells, as seen in restenosis (intimal hyperplasia) of coronary arteries following balloon angioplasty or bypass surgery. Local administration of FTIs or geranylgeranyl transferase inhibitors (GGTIs) can prevent restenosis by blocking neointima formation<sup>191</sup>. GGTIs may also assist in the therapy of cardiovascular diseases by increasing nitric oxide synthase expression<sup>192</sup>.

Parasitic diseases such as malaria, Chagas disease, African sleeping sickness, Toxoplasmosis and Leishmaniasis cause millions of deaths in tropical and subtropical regions, and the therapeutic potential of FTIs for these diseases has also been explored<sup>193</sup>. FTIs specifically designed to inhibit parasitic FT and not mammalian FT are significantly more toxic to parasitic protozoa<sup>194,195</sup>. Recently, a GGT1 from *Trypanosoma cruzi*, the parasite responsible for Chagas disease, was cloned<sup>196</sup>, and GGTIs may also be effective against these diseases.


FTIs also show strong antiviral activity in mice infected with the hepatitis  $\delta$  virus<sup>197</sup>. Other diseases that may also be amenable to therapy with prenyltransferase (PT) inhibitors (PTIs) are multiple sclerosis<sup>198</sup> and metabolic bone disorders<sup>199</sup>, as well as a wide variety of undesirable fibrotic reactions<sup>200</sup>.



**Figure 1. RAS signalling pathways in mammalian cells**

Active (farnesylated, membrane-bound and GTP-bound) RAS modulates a number of signalling pathways. Oncogenic RAS mutations tend to lock RAS in its GTP-bound state, resulting in constitutive RAS signalling. The major RAS effector pathways are shown. The two best-studied pathways that are activated by RAS are the RAF–MEK–MAPK signalling cascade and the PI3K–AKT pathway. The RAF–MEK–MAPK pathway ultimately activates the ETS family of transcription factors, which induce multiple genes that promote cell cycle progression and cell migration. Likewise, AKT phosphorylates multiple cellular proteins, leading to the inhibition of several tumour suppressors (such as p27, p53, tuberous sclerosis 1 (TSC1), TSC2 and BCL-2 antagonist of cell death (BAD)) or leading to the activation of several oncogene products. RAS also activates other small GTPases such as RALA and RALB, which have recently been shown to mediate RAS transformation in human pancreatic tumours, for example. Farnesyltransferase inhibitors (FTIs) were originally developed to block the function of RAS. However, as numerous studies *in vitro* and *in vivo* have shown, their antitumour activity is not correlated to the mutation status of KRAS isoforms. This suggests that the antitumour activity of FTIs relies on blocking the activity of other prenylated proteins. However, the inhibition of RAS protein function may still be important, particularly for tumours with mutant HRAS and tumours addicted to wild-type RAS. CDC42, cell division cycle 42; DAG, diacylglycerol; FOX, forkhead transcription factor; GAP, GTPase-activating protein; GEF, guanine nucleotide exchange factor; IKK, IκB kinase; IP3, inositol-1,4,5-trisphosphate; mTORC, mTOR complex; NF-κB, nuclear factor-κB; PDK1, phosphoinositide-dependent kinase 1; PKC, protein kinase C; PLA, phospholipase A; PLCε, phospholipase Cε; PLD, phospholipase D; RALGDS, RAL guanine nucleotide dissociation stimulator; RHEB, RAS homologue enriched in brain; RIN1, RAS and RAB interactor 1; TIAM1, T cell lymphoma invasion and metastasis 1.





**Timeline.**

**Protein prenylation and human cancer**

FT, farnesyltransferase; FTI, FT inhibitor; GGT1, geranylgeranyl transferase 1; RCE1, RAS-converting enzyme 1.

**Table 1**

Effects of PT-targeted gene deletions

| Affected gene product                         | Animal model                    | Type of gene deletion | Tissue               | Phenotypes   | Refs |
|---|---------------------------------|-----------------------|----------------------|--|------|
| GGT1 $\beta$ -subunit                         | <i>Saccharomyces cerevisiae</i> | Constitutive          | NA                   | Lethal   | 32   |
| GGT1 $\beta$ -subunit                         | <i>Drosophila melanogaster</i>  | Constitutive          | NA                   | Lethal   | 33   |
| FT $\beta$ -subunit                           | Mouse                           | Constitutive          | NA                   | Embryonically lethal   | 31   |
|   |                                 | Conditional           | Lung                 | <ul style="list-style-type: none"> <li>• Delayed wound healing*</li> <li>• No effect on tumour initiation*</li> <li>• Lack of tumour progression*</li> </ul>   | 31   |
|   |                                 | Conditional           | Lung                 | Lack of HRAS association with cell membranes   | 37   |
|   |                                 | Conditional           | Haematopoietic cells | Delay of KRAS-induced lung tumours<br>Reduced severity of MPD  | 38   |
| GGT1 $\beta$ -subunit                         | Mouse                           | Conditional           | Lung                 | <ol style="list-style-type: none"> <li>1 Disruption of actin cytoskeleton</li> <li>2 Reduced cell migration</li> <li>3 Cell cycle arrest of embryonic fibroblasts</li> <li>4 Inhibition of KRAS-induced lung tumour formation</li> </ol> | 34   |
| FT $\beta$ -subunit and GGT1 $\beta$ -subunit | Mouse                           | Conditional           | Lung                 | <ol style="list-style-type: none"> <li>1 Significant delay of KRAS-G12D-induced lung tumour onset</li> <li>2 Increased lifespan</li> </ol>   | 37   |

FT, farnesyltransferase; GGT1, geranylgeranyltransferase 1; MPD, myeloproliferative disease; NA, not applicable; PT, prenyltransferase.

\* Owing to a 'leaky' null allele these results have been called into question<sup>36</sup>.

**Table 2**

Clinical trials with FTIs\*

| Disease                                 | Phase | Patients (median age) | Clinical response and number of patients <sup>‡</sup> | FT activity or prenylation                          | Response rate (%) | Other comments   |
|---|-------|-----------------------|---|---|-------------------|--|
| <b>Tipifarnib</b>                       |       |                       |   |   |                   |  |
| Acute leukaemia                         | I     | 34 (63)               | 2 CR and 8 PR   | FT ↓ <sup>§</sup> and HDJ2 ↓                        | 29.4              | No NRAS mutations in patient tumours   |
| Advanced bladder cancer                 | II    | 34 (64)               | 2 PR and 13 SD  | ND  | 5.9               | Response rate does not warrant further investigation                         |
| Advanced breast cancer                  | II    | 76 (54)               | 9 PR and 9 SD   | ND  | 11.8              | All responders had wild-type RAS genes                                       |
| Advanced colon cancer                   | II    | 55 (69)               | 1 PR, 11 SD, and 31 PD and MD                         | ND  | 1.8               | Tipifarnib is ineffective  |
| Advanced NSCLC                          | II    | 44 (71)               | 7 SD  | HDJ2 ↓ and preliminary A ↓, FT ↓ in 83% of patients | 0                 | No objective response. Future studies should be done with combinations       |
| Advanced solid tumours                  | I     | 25 (58)               | 0 CR, 0 PR, 8 SD, and 17 PD and MD                    | Data not shown                                      | 0                 | No objective response  |
| Advanced solid tumours                  | I     | 9 (53)                | 1 SD, and 8 PD and MD                                 | ND  | 0                 | No objective response  |
| Advanced solid tumours                  | I     | 28 (56)               | 2 PR and 3 SD   | ND  | 7.1               | 5 of 15 patients had KRAS mutations  |
| Advanced solid tumours                  | I     | 21                    | 6 SD  | ND  | 0                 | No objective response. Phase II trial recommended                            |
| AML                                     | II    | 252 (62)              | 11 CR and 8 PR  | ND  | 7.5               | MS for patients with CR: 369 days  |
| AML                                     | II    | 145 (74)              | 22 CR, 3 PR, 50 SD and 58 PD and MD                   | HDJ2 ↓  | 17.2              | Median duration of CR: 7.3 months  |
| AML                                     | III   | 228 (76)              | 18 CR, 20 PR, 105 SD, and 36 PD and MD                | ND  | 16.7              | MS: 107 days, 8% of patients had a CR with an MS of 666 days                 |
|   |       | 229 <sup>¶</sup>      | 0 CR, 3 PR, 130 SD, and 46 PD and MD                  |   | 1.3               | MS: 109 days   |
| Brain tumours                           | II    | 81 (11)               | 2 PR  | ND  | 2.5               | Very little activity   |
| CML, myelofibrosis and multiple myeloma |       | 40 (57)               | 7 CR and 7 PR   | ND  | 17.5              | Clinical activity in CML and myelofibrosis                                   |
| Metastatic pancreatic cancer            | II    | 20 (61)               | 1 SD  | FT ↓ by 50% and HDJ2 ↓ by 33%                       | 0                 | No objective response. MS: 19.7 weeks  |
| Multiple myeloma                        | II    | 36 (62)               | 0 CR, 0 PR, 23 SD, and 13 PD and MD                   | FT ↓ and HDJ2 ↓                                     | 0                 | No objective response. No correlation between FT ↓ and disease stabilization |

| Disease  | Phase | Patients (median age) | Clinical response and number of patients <sup>‡</sup> | FT activity or prenylation | Response rate (%) | Other comments   |
|--|-------|-----------------------|---|----------------------------|-------------------|--|
| MDS  | I     | 20 (66)               | 1 CR, 5 PR, and 1 PD and MD                           | FT ↓ and HDJ2 ↓            | 30                | No correlation between FT ↓ and response. No correlation between RAS mutation status and response    |
| MDS  | II    | 27 (66)               | 2 CR and 1 PR   | ND                         | 11.1              | Modest antitumour activity   |
| MDS  | II    | 82 (67)               | 26 PR and 37 SD                                       | ND                         | 31.7              | Median duration of CR: 11.5 months   |
| MDS  | I     | 61 (68)               | 3 CR and 13 PR  | FT ↓ by 75%                | 26.2              | Only one responder with a KRAS mutation. No correlation between FT ↓ and dose                        |
| Neuro-fibromatosis and neurofibromas                       | I     | 40 ( 15)              |   | FT ↓ by 43% and HDJ2 ↓     | 0                 | No objective response  |
| Pancreatic cancer  | II    | 53 (65)               |   | ND                         | 0                 | No objective response. MS: 2.6 months  |
| Small-cell lung cancer                                     | II    | 20 (62)               | 1 SD  | ND                         | 0                 | No objective response. MS: 6.8 months. Progression-free MS: 1.4 months                               |
| Advanced colon cancer                                      | III   | 235 (61)              | 0 CR, 1 PR, 57 SD, and 155 PD and MD                  | ND                         | 0.4               | MS: 174 days. SD >3 months: 24%  |
|  |       | 133 <sup>#</sup> (62) | 0 CR, 0 PR, 17 SD, and 107 PD and MD                  |                            | 0                 | MS: 185 days. SD >3 months: 13%  |
| <b>Lonafarnib</b>  |       |                       |   |                            |                   |  |
| Advanced solid tumours                                     | I     | 24 (57)               | 0 CR, 0 PR and 2 SD                                   | ND                         | 0                 | No objective response  |
| Advanced solid tumours                                     | I     | 12 (61)               | 0 CR and 0 PR   | Prelamin A ↓               | 0                 | No objective response  |
| Advanced solid tumours                                     | I     | 22 (54)               | 1 CR and 1 PR   | FT ↓                       | 12.5 <sup>#</sup> | Sponsor terminated study early owing to negative interim efficacy. FT ↓ not correlated with response |
| Advanced solid tumours                                     | II    | 15 (57)               | 0 CR, 0 PR and 7 SD                                   | ND                         | 0                 | No objective response  |
| CML  | Pilot | 13 (62)               | 0 CR and 2 PR   | ND                         | 15.5              |  |
| CNS tumours  | I     | 48 (12)               | 0 CR, 1 PR and 9 SD                                   | ND                         | 2.1               |  |
| Metastatic colon cancer                                    | II    | 21 (64)               | 0 CR, 0 PR and 3 SD                                   | ND                         | 0                 | No objective response  |
| MDS or sAML  | II    | 16 (70)               | 1 PR  | ND                         | 6.7               |  |
| NSCLC  | II    | 29 (58)               | 3 PR, 11 SD, and 15 PD and MD                         | ND                         | 10.3              | MS: 39 months. Well-tolerated. Further clinical trials recommended                                   |
| Refractory urothelial cancer (transitional cell carcinoma) | II    | 10 (65)               | 0 CR, 0 PR, 2 SD, and 8 PD and MD                     | Small HDJ2 ↓               | 0                 | No objective response  |
| Solid tumours  | I     | 20 (59)               | 1 PR and 8 SD   | Prelamin A ↓               | 5.0               |  |
| <b>BMS-214662</b>  |       |                       |   |                            |                   |  |

| Disease                | Phase | Patients (median age) | Clinical response and number of patients <sup>‡</sup> | FT activity or prenylation | Response rate (%) | Other comments  |
|------------------------|-------|-----------------------|---|----------------------------|-------------------|---|
| Acute leukaemia        | I     | 30 (53)               | 4 CR and 1 PR   | Short-lived FT ↓           | 16.7              |   |
| Advanced solid tumours | I     | 44 (54)               | 0 CR, 0 PR and 1 SD                                   | Transient FT ↓ by 89.5%    | 0                 | No objective response. One patient with pancreatic cancer survived for >3.5 years |
| Advanced solid tumours | I     | 68 (60)               | 0 CR, 0 PR and 5 SD                                   | Short-lived FT ↓           | 0                 | No objective response   |
| Advanced solid tumours | I     | 19 (55)               | 1 SD, and 18 PD and MD                                | ND                         | 0                 | No objective response   |
| Solid tumours          | I     | 25 (57)               | 1 PR, 16 SR, and 8 PD and MD                          | Short-lived FT ↓           | 4.0               | Response was minor  |

AML, acute myeloid leukaemia; CML, chronic myeloid leukaemia; CNS, central nervous system; CR, complete response; FNTB, farnesyltransferase  $\beta$ -subunit; FT, farnesyltransferase; FTIs, FT inhibitors; GGTI, geranyltransferase I inhibitor; HI, haematological improvement; MD, metastatic disease; MDS, myelodysplastic syndrome; MS, median survival; ND, not determined; NSCLC, non-small-cell lung cancer; OS, overall survival; PD, progressive disease; PR, partial response; sAML, secondary acute myeloid leukaemia; SD, stable disease.

\* See Supplementary information S4 (table) for a table with references. This table only considers FTIs because, to our knowledge, only one GGTI, GGTI-2418, is currently in clinical trials. Studies that did not evaluate tumour response are not included. Median ages are rounded to the closest integer. The number of evaluable patients is stated whenever possible. The response rate was calculated by dividing the sum of complete and partial responses by the number of evaluable patients.

<sup>‡</sup> PR includes haematological improvement.

<sup>§</sup> Downward arrows indicate a reduction of enzyme activity (in the case of FT) or a reduction in farnesylation (in the case of HDJ2 or prelamin A).

<sup>||</sup> This patient cohort received best supportive care.

<sup>¶</sup> In this study all patients received best supportive care, with 235 receiving tipifarnib and 133 receiving a placebo.

<sup>#</sup> Number differs from the authors' calculation as they included SD, resulting in a response rate of 37.5%.

**Table 3**

Clinical trials with combinations including FTIs\*

| Drugs                                       | Disease                      | Phase    | Patients (median age) | Clinical response and number of patients <sup>§</sup> | FT activity or prenylation     | Response rate (%) | Other comments  |
|---|------------------------------|----------|-----------------------|---|--------------------------------|-------------------|---|
| Tipifarnib + capecitabine                   | Advanced solid tumours       | I        | 41 (57)               | 5 PR and 11 SD  | FT ↓,§ and HDJ2 ↓              | 12.2              | No correlation between FT ↓ and response                  |
| Tipifarnib + doxorubicin + cyclophosphamide | Advanced breast cancer       | I and II | 32 (51)               | 7 CR  | FT ↓ by 55–100%                | 21.9              |   |
|   | Stage IIB–IIIC breast cancer | II       | 44 (51)               | 11 CR   | Median FT ↓ by 91%             | 25                |   |
| Tipifarnib + etoposide                      | AML                          | I        | 84 (77)               | 20 CR   | p-S6 ↓                         | 23.4              |   |
| Tipifarnib + gemcitabine                    | Advanced solid tumours       | I        | 19 (59)               | 2 PR  | HDJ2 ↓                         | 10.5              |   |
| Tipifarnib + gemcitabine                    | Advanced pancreatic cancer   | III      | 341 (61)              | 6 CR, 6 PR, 53 SD, and 28 PD and MD                   | ND                             | 1.8               | MS: 193 days. 6-month survival: 53%. 1-year survival: 27% |
|   |                              |          | 347 <sup>¶</sup> (62) | 8 CR, 8 PR, 52 SD, and 30 PD and MD                   | ND                             | 2.3               | MS: 182 days. 6-month survival: 49%. 1-year survival: 24% |
| Tipifarnib + gemcitabine + cisplatin        | Advanced solid tumours       | I        | 27 (58)               | 1 CR and 8 PR   | Prelamin A ↓                   | 33.3              |   |
|   | Advanced solid tumours       | I        | 31 (58)               | 8 PR and 12 SD  | ND                             | 25.8              | Phase II trial recommended                                |
| Tipifarnib + idarubicin + cytarabine        | AML and MDS                  | I/II     | 95 (50)               | 61 <sup>#</sup> CR and 9 PR                           | ND                             | 74                | MS: 17 months   |
|   |                              |          | 108 <sup>¶</sup> (52) | 65 <sup>#</sup>                                       |                                | 70                | MS: 13 months   |
| Tipifarnib + imatinib                       | CML                          | I        | 25 (62)               | 17 PR   | ND                             | 68                | 11 patients withdrew (lack of response)                   |
| Tipifarnib + irinotecan                     | Solid tumours                | I        | 35 (52)               | 3 PR, 14 SD, and 13 PD and MD                         | ND                             | 8.6               |   |
| Tipifarnib + letrozole                      | Advanced breast cancer       | II       | 74 (60)               | 3 CR, 19 PR, 29 SD, and 23 PD and MD                  | ND                             | 29.7              | No improvement by tipifarnib                              |
|   |                              |          | 39 <sup>¶</sup> (61)  | 1 CR, 14 PR, 15 SD, and 9 PD and MD                   | ND                             | 38.5              |   |
| Tipifarnib + sorafenib                      | Advanced solid tumours       | I        | 43 (56)               | 3 PR, 15 SD, and 20 PD and MD                         | 25% of patients with >50% FT ↓ | 7.0               |   |
| Tipifarnib + tamoxifen                      | Metastatic breast cancer     | I        | 12 (50)               | 2 PR and 1 SD   | FT ↓ 42–54%                    | 16.7              |   |

| Drugs                                 | Disease                    | Phase | Patients (median age) | Clinical response and number of patients <sup>‡</sup> | FT activity or prenylation  | Response rate (%) | Other comments   |
|---------------------------------------|----------------------------|-------|-----------------------|---|-----------------------------|-------------------|--|
| Lonafarnib + carboplatin + paclitaxel | Advanced NSCLC             | III   | 308 (unknown)         | 308 <sup>//</sup> (unknown)                           | NA                          | NA                | OS: 144 days. TTP: 137 days  |
| Lonafarnib + docetaxel                | Advanced solid tumours     | I     | 29                    | 1 CR and 6 SD   |                             | 3.4               | OS: 168 days. TTP: 152 days<br>Response (CR + SD) correlates with low FNTB mRNA levels |
| Lonafarnib + gemcitabine              | Advanced bladder cancer    | II    | 31 (64)               | 1 CR and 9 PR   | ND                          | 32.3              | MS: 11.5 months. TTP: 7 months   |
| Lonafarnib + imatinib                 | CML                        | I     | 23 (55)               | 6 CR and 2 PR   | ND                          | 34.7              |  |
| Lonafarnib + paclitaxel               | Solid tumours              | I     | 21 (60)               | 6 PR  | ND                          | 28.6              | 6 patients previously treated  |
| BMS-2/4662 + cisplatin                | Advanced solid tumours     | I     | 23 (57)               | 15 SD   | Short-lived FT ↓            | 0                 | No objective response  |
| BMS-2/4662 + paclitaxel               | Advanced solid tumours     | I     | 26 (60)               | 2? PR   | Short-lived FT ↓            | 7.7               |  |
| BMS-2/4662 + paclitaxel + carboplatin | Advanced solid tumours     | I     | 30 (58)               | 3 PR and 8 SD   | Short-lived FT ↓ and HDJ2 ↓ | 10.0              | No correlation between dose and HDJ2 ↓   |
| L-778,123 + radiotherapy              | Advanced solid tumours     | I     | 7 (59)                | 5 CR, 1 PR, and 6 PD and MD                           | ND                          | 85.7              | No RAS mutations   |
|                                       | Advanced pancreatic cancer | I     | 10 (59)               | 1 PR, 5 SD, and 4 PD and MD                           | HDJ2 ↓                      | 10.0              | 3 out of 4 patients examined have KRAS mutations                                       |

AML, acute myeloid leukaemia; CML, chronic myeloid leukaemia; CR, complete response; FNTB, farnesyltransferase β-subunit; FT, farnesyltransferase; FTIs, FT inhibitors; GGTI, geranylgeranyltransferase 1 inhibitor; HI, haematological improvement; MD, metastatic disease; MDS, myelodysplastic syndrome; MS, median survival; NA, not applicable; ND, not determined; NSCLC, non-small-cell lung cancer; OS, overall survival; p, phosphorylated; PD, progressive disease; PR, partial response; S6, ribosomal protein S6; SD, stable disease; TTP, median time to progression.

\* See Supplementary information S5 (table) for a table with references. This table only considers FTIs because, to our knowledge, only one GGTI, GGTI-2418, is currently in clinical trials. Studies that did not evaluate tumour response are not included. Median ages are rounded to the closest integer. The number of evaluable patients is stated whenever possible. The response rate was calculated by dividing the sum of complete and partial responses by the number of evaluable patients.

<sup>‡</sup> PR includes haematological improvement.

<sup>§</sup> Downward arrows indicate a reduction of enzyme activity (in the case of FT) or a reduction in farnesylation (in the case of HDJ2 or prelamin A).

<sup>//</sup> This patient cohort received a placebo instead of the FTI.

<sup>¶</sup> This patient cohort received idarubicin plus cytarabine (referred to by the authors as a historical control).

<sup>#</sup> As the reference only provides percentage response rates, the patient numbers were calculated.